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ABBREVIATIONS 
LEDI             -          Ledipasvir 
SOFO            -          Sofosbuvir 
Hrs            -      Hours 
HPLC        -       High Performance Liquid Chromatography 
HPTLC     -      High Performance Thin Layer Chromatography 
ICH           -       International conference on harmonization 
LOD          -       Limit of detection 
LOQ          -      Limit of quantification 
min            -       Minute 
RP-HPLC  -      Reverse phase high performance liquid chromatography 
RSD          - Relative standard deviation 
UV             - Ultra violet 
AS - Asymmetric factor 
gm          - Gram 
M                - Molar 
Mg              - Milligram 
mL              - Millilitre 
mM             - Millimolar 
mm             - Millimeter 
ng             - Nanogram 
Rf                  - Retardation factor 
Rs                 - Resolution 
Rt              - Retention time 
Tf                  - Tailing factor 
ȝg             - Microgram 
ȝL            - Microlitre 
Ȝmax            - Wavelength of maximum absorbance 
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INTRODUCTION [1-9] 
            Pharmaceutical analysis may be defined as the application of analytical 
procedures used to determine the purity, safety and quality of drugs and chemicals. 
Most manufacturing industries rely upon both qualitative and quantitative chemical 
analysis to ensure that the raw materials used meet certain specifications, and also 
to check the quality of the final product. The examination of raw materials is carried 
out to ensure that there are no unusual substances present which might be 
deleterious to the manufacturing process or appear as a harmful impurity in the final 
product. The final manufactured product is subjected to quality control to ensure 
that its essential components are present within a pre-determined range of 
composition, whilst impurities do not exceed certain specified limits.   
 
Reasons for developing newer analytical methods for drugs: 
 Marketed drug may not be official in pharmacopoeias. 
 Literature search may not contain complete analytical procedure for 
           such drugs. 
 No proper method may be available for drug in the form of formulation  
           due to interference caused by pharmaceutical excipients. 
 Procedures for the estimation of drug in biological fluids may not be 
 available. 
 Analytical techniques may not be available for the drugs in      
           combination with other drugs. 
 Expenses may be more for reagents and solvents used in existing 
 procedures. 
 There may be difficulties in extraction and separation process and  
           these may not be sensitive and time consuming. 
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Analytical Techniques 
 The instrument techniques employed for the drug analysis can be 
categorized into following techniques such as: 
 Spectrophotometric techniques 
 Electrochemical techniques 
 Chromatographic techniques 
 Hyphenated techniques 
 Miscellaneous techniques 
UV-VISIBLE SPECTROSCOPY  
 The technique of UV-Vis spectrophotometry is one of the most frequently 
employed in pharmaceutical analysis. It involves the measurement of amount of 
ultraviolet (190-380 nm) or visible (380-800 nm) radiation absorbed by a substance 
in solution. Absorption of light in both the ultraviolet and visible regions of the 
electromagnetic spectrum occurs when the energy of the light matches that required 
to induce in the molecule an electronic transition and its associated vibrational and 
rotational transitions.   
 Many molecules absorb ultraviolet or visible light. The absorbance of a 
solution increases as the attenuation of beam increases. Absorbance is directly 
proportional to the absorptivity, a, path length, b, and the concentration, c, of the 
absorbing species. Beer's Law states that  
A = abc 
Optimum conditions for spectrophotometric measurement 
 In developing an analytical method based on UV visible spectrophotometry 
most appropriate sample and instrumental conditions are required. The accuracy 
and precision of spectrophotometric measurements depend on the intensity of stray 
light and the choice of  sample conditions(solvents, concentration and path length) 
and instrumental parameters(wavelength, slit width and scan speed). 
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Selection of solvent 
 The choice of solvent is governed by the solubility of absorbing substance 
and by the absorption of the solvent at the analytical wavelength. The solubility of 
the substance in polar and non-polar solvents can often be predicted from a 
consideration of its chemical structure. 
Selection of analytical wavelength 
 In spectrophotometer the wavelength of maximum absorbance is selected 
by wavelength scan, the wavelength at which the maximum absorbance was 
attained when scanned in the range of 200-400 nm was selected as detection 
wavelength for the method. 
SIMULTANEOUS EQUATION METHOD 
              If a sample containing two absorbing drugs (X and Y) each of which 
absorbs at the λmax of the other , it may be possible to determine both drugs by 
simultaneous equation method(vierodt’s method. 
            Cx = A2ay1- A1ay2 / ax2ay1- ax1 ay2            
            Cy = A2ax2- A1ax1 / ax2ay1- ax1 ay2 
  
Where, 
 
Cx and Cy = Concentration of both drug respectively  
A1 and A2 = Absorbance’s of the unknown sample at λ1 and λ2 respectively 
ax1 and ax2= Absorptivity’s of the unknown sample (x) at λ1 and λ2 respectively 
ay1 and ay2 = Absorptivity’s of the unknown sample (y) at λ1 and λ2 respectively 
      
 The criteria are satisfied only when the λmax of the two components are 
reasonably dissimilar and additional criterion is that the two components do not 
interact chemically. 
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DERIVATIVE SPECTROPHOTOMETRY  
 Derivative spectrophotometry is mainly used in the process of conversion 
of a simple spectrum in to its first, second or higher order derivative spectrum. The 
transformations that occur in the derivative spectra are understood by reference to 
a Gaussian band which represents an ideal absorption band. 
 The second derivative (D2) spectrum is a plot of the d2A/d λ2 vs. λ. It is 
characterized by two satellite maxima and an inverted band of which the minimum 
corresponds to the λmax of the fundamental band. 
 These spectral transformations confer two principal advantages on 
derivative spectrophotometry. 
1. Derivative spectrum shows better resolution of overlapping bands than the 
fundamental spectrum and may permit the accurate determination of the λ 
max of the individual bands, 
2. Derivative spectrophotometry discriminates in favour of substances of 
narrow spectral bandwidth against broad bandwidth substances. 
 The substances of narrow spectral bandwidth display larger derivative 
amplitudes than those of broad bandwidth substances. 
 These advantages of derivative spectrophotometry, enhanced resolution and 
bandwidth discrimination, permit the selective determination of certain absorbing 
substances in samples, and most importantly, to reduce the effects of interference 
from scattering, matrix, or other absorbing compounds in quantitative analysis. 
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INSTRUMENTATION OF UV-VISIBLE SPECTROSCOPY 
 
 
CHROMATOGRAPHY  
 Chromatography is defined as a method of separating a mixture of 
components into individual components through equilibrium distribution between 
two phases. The technique of chromatography is based on the differences in the rate 
at which the components of a mixture move through a porous medium (called 
stationary phase) under the influence of some solvent or gas (called moving phase). 
 The chromatographic method of separation, in general, involves the 
following steps: 
 Adsorption  
 Separation of the adsorbed substances by the mobile phase. 
 Recovery of the separated substances by a continuous flow of the mobile  
            phase; the method being called elution. 
 Qualitative and quantitative analysis of the eluted substances.  
 HPLC and HPTLC comes under the classification of liquid chromatography   
and principle involved in the separation of components is adsorption. 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRPHY  
 HPTLC is a versatile separation powerful, reliable and efficient method of 
quantitative and qualitative analysis, HPTLC can simultaneously handle several 
samples even of divergent nature and composition supporting several analysts at a 
given time. HPTLC is the most simple separation technique today available to the 
analyst. It is considered as a time machine that can speed up your work and allows 
you to do many things at a time usually not possible with other analytical 
techniques. 
             The basic difference between conventional TLC and HPTLC is particle and 
pore size. In HPTLC high performance grade of silica in which the particle are small 
about 5µm and very uniform in size are used. The high performance silica gel gives 
more efficient and reproducible separation than conventional grade of silica. The 
plates are smaller and the development time is shorter. 
Principle  
 HPTLC is one of the most widely used methods for both quantitative and 
qualitative analysis. The principle of separation is adsorption. The mobile phase 
flows through because of capillary action. The components are separated based on 
the affinity of the components towards the stationary phase.  
Advantages of HPTLC: 
 Visual chromatogram and simplicity 
 Multiple sample handling  
 Quantification of crude drugs 
 Simultaneous analysis of samples 
 Small quantity of mobile is required  
 Automatic sample application  
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Various steps involved in HPTLC chromatography 
 
 
 
             
    Selection and optimization         Pre-washing  
                        of mobile phase             of pre-coated plates 
 
                                                              
                   Saturation of chamber          pre-conditioning of layer                                                                                                        
                         
 
                                                       
  
             
                      UV-Visible/fluorescent            
 
 
 
 
 
 
 
Selection of sorbent layers 
Sample and standard preparation 
Application of standard and the sample 
Chromatographic development   
Quantitative evaluation 
Detection of analytes 
Documentation 
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There are different HPTLC plates available: 
 Hand-made plates(self-prepared layers) 
 Pre-coated plates 
 Polyester sheets 
 Glass support  
 Aluminium sheets 
Plate size 
 Pre-coated HPTLC plates in size of 20×20 with aluminium or polyester 
support are usually procured mainly for economic reasons. These plates can be cut 
into size and shape to suit a particular analysis. 
Sample preparation 
 Proper sample preparation is an important pre-requisite for successful 
chromatographic separation. The sample preparation procedure is to dissolve the 
dosage form with complete recovery of intact compounds of interest and minimum 
of matrix with a suitable concentration of analytes for direct application on the 
HPTLC plate.  
Choice of solvent for the sample 
 It should dissolve the analytes. 
 It should be reasonably volatile. 
 It should have low viscosity. 
 It should wet the sorbent layer. 
Sample application 
 This is the most critical step for obtaining good resolution for quantification 
by HPTLC. Automatic application devices are recommended for quantitative 
analysis. The advantages of application of sample as band are even distribution of 
the sample, better resolution and greater accuracy. Application in small increments 
has disadvantage. 
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Chamber saturation: 
 Chamber saturation has pronounced influence on the separation profile. 
When the plate is introduced into an unsaturated chamber, during the course of 
development, the solvent evaporates from the plate mainly at the solvent front. 
Therefore larger quantity of the solvent shall be required for a given distance, hence 
resulting in increase in Rf values. If the tank is saturated prior to development, 
solvent vapours soon get uniformly distributed throughout the chamber. 
Chromatographic development  
               The precoated plate then placed in the saturated chamber containing 
mobile phase and allowed to run the desired running distance and then kept out for 
drying.  
Detection: 
  After completion of the development process the plate is removed from the 
chamber and dried to remove the mobile phase completely. The zone can be 
visualized by various physical and chemical methods. There is apparently no 
difficulty in detecting coloured substances or colourless substances absorbing in 
shortwave ultraviolet region. The substances which do not have such properties 
have to be transferred into detectable substances by means of using 
chromatographic reagents. Detection under UV light is the first choice and non-
destructive in most cases and is commonly employed for densitometric scanning.   
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HIGH PERFORMANCE LIQUID CHROMATOGRAPH 
       A variety of methods are available for analysing pharmaceutical compounds; 
however HPLC is currently the method of choice for the analysis of these compounds. 
HPLC offers high performance over ambient pressure or low pressure liquid 
chromatography. 
       High performance liquid chromatography is used in analytical development to 
quantitate the active pharmaceutical ingredient (API) and to evaluate impurity and 
degradation product profiles of drugs substances and drug products. Additional uses of 
HPLC include the determination of content uniformity of dosage forms, monitoring of 
dissolution profiles, determination of antioxidant and microbial preservative content 
and support of cleaning validations. Separation of these types require only a monitoring 
of one, or a limited number of predefined compounds. A significantly larger challenge 
is presented in the composite assays of drug substances and drug products where the 
goal is to quantitate API and relevant impurities and degradation products in a single 
chromatographic run. 
 The development of any new or improved method usually tailors existing 
approaches and instrumentation to the current analyte, as well as to the final needs or 
requirements of the method. Method development usually requires selecting the 
requirements and deciding on what type of instrumentation to utilize at the 
development stage, decisions regarding  
                  Choice of column, 
                   Mobile phase, 
                   Detector(s) and 
                   Method of quantitation must be addressed.  
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Goals for new or improved HPLC method might include the following: 
1. Qualitative identification; the specific analyte(s) of interest, providing some 
 structural information to confirm general behaviour( i.e. retention time, pH) 
2. Quantitative determination; at trace level when necessary ( i.e. accurate, precise 
and reproducible in any laboratory setting when performed according to 
established procedures). 
3. Ease of use, ability to be automated, high sample throughout and rapid sample 
 turn around time. 
4. Sample preparation that minimizes time, effort, materials and volume of sample 
 consumed.  
The following criteria are to be met for developing method: 
i. For drug substances 
 Methods should separate the API, synthetic process impurities, and drug 
substances and degradation products. Methods should be able to detect impurities and 
degradation products present at level greater than 0.05% relative to the API. Impurities 
and degradation products present at the levels greater than 0.1% should be identified 
and specifications should be placed on limits. 
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ii. For drug products 
 Methods should separate the API, drug products degradation products from 
excipients. Drug products methods are not required to monitor synthetic process 
impurities, unless they are also drug product degradation products. Methods should be 
able to detect degradation products present at level greater than 0.1% relative to API. 
Degradation products present at level greater than 0.2% should be identified and 
specifications should be placed on limits.                                  
Types 
 Most commonly used methods in chromatography are as follows: 
 Normal–phase chromatography: 
          Normal phase chromatography depends upon the interaction of stationary 
phase’s polar surface with polar parts of the sample molecules. 
 Reversed-phase chromatography: 
       The mechanism is retention by interaction of stationary phase’s non-polar 
hydrocarbon chain with non-polar parts of the sample molecules.  
 Reversed phase ion-pair chromatography: 
          The technique is based on ionic sample molecules that are ionically bound 
to an ion-pair reagent. The ion-pair reagent contains an unpolar part suitable for 
interaction with the unpolar hydrocarbon chain of the stationary phase. 
 Ion-exchange chromatography: 
           Ion-exchange chromatography is due to the retention by reversible ionic 
bonds to charged groups on the stationary phase. 
 System suitability parameters  
 Parameters concerning column specification and performance are needed 
for use in method development and they are as follows: 
  Introduction 
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 Plate number (N): 
 The column plate number (N) is an important characteristic of a column. N 
defines the ability of the column to produce sharp, narrow peaks for achieving good 
resolution of band pairs with small values. 
  N = 13500 L (cm) 
       dp (µm) 
Where,    L      = Column length 
              TR     = Band retention time 
              dp     = Diameter of the particle 
 Peak asymmetry and peak tailing: 
 Peak shape is important in method development. Peaks with poor symmetry 
can result in: 
* Inaccurate plate number and resolution measurement 
* Imprecise quantitation 
* Degraded resolution and undetected minor bands in the peak tail 
 * Poor retention reproducibility 
           A useful and practical measurement of peak shape is the peak asymmetry 
factor, As. Peak asymmetry is measured at 10% of full peak height. Good columns 
produce peaks with As values of 0.95 to 1.1. 
 Another useful way to define peak shape is the tailing factor and is 
calculated at 5% of full peak height. 
Peak asymmetry factor = B/A 
Peak tailing factor = A+B/2A 
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Where, A  =  Distance between the perpendicular connecting the baseline to 
  the peak maximum and the earliest eluting portion of the curve 
 B  =  Distance between the perpendicular connecting the baseline to the 
peak    maximum and the latest eluting portion of the curve 
 Retention:  
 The retention of a drug with a given packing material and eluent can be 
expressed as retention time or retention volume, but both of this are dependent on 
flow rate, column length and column diameter. The retention is best described as a 
column capacity ratio (k), which is independent of these factors. The column 
capacity ratio of a compound (A) is defined as 
o
oA
o
oA
A t
tt
V
VVk 
 
Where,      VA = Elution volume of A 
                  V0 = Elution volume of a non-retained compound (void volume) 
 Resolution: 
 Measure of quality of separation of adjacent bands and it is calculated 
from width and retention time of two peaks or separation of two peaks.  
    Rs =    2(t2-t1) 
               W1+W2 
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 Where,   t1 and t2         = Retention time of first and second adjacent bands for   
     the latest and the earliest eluting peak     
               W1 and W2   = Baseline bandwidth  
                 RS ≥ 1       = Components completely separated 
                 RS ≤ 1       = Component overlap 
 
 Capacity Factor (k’): 
 Capacity factor is the measure of position of a sample peak in the 
chromatogram. It is a parameter which specifies the extent of the delay of a 
substance to be separated. It depends upon stationary phase, mobile phase, 
temperature and quality of column packing. 
 For good chromatographic performance with isocratic separation, k’ value 
should be in the range of 1-10. If k’ is less than 1; the bands are inadequately 
separated from unretained material eluting at t0 and if k’ is more than 10; separation 
takes too long and bands broadened. 
k’1 =  tR1– t0 / t0       , 
                                                   k’2  = tR2– t0 / t0   
Where,      tR= Retention time
 
                 t0 = Void volume      
 
 Separation Factor (α):  
 Separation factor is also known as selectivity. It is the measure of peak 
spacing and is expressed as           
1
2
K
K


 
Where,       subscripts refer to the order of elution. 
                  α is always ≥ 1     
 
  Introduction 
 
 
 
Department of Pharmaceutical Analysis  16 
FORCED DEGRADATION STUDIES  
 Chemical stability of pharmaceutical molecules is a matter of great concern 
as it affects the safety and efﬁcacy of the drug product. The FDA and ICH guidance’s 
state the requirement of stability testing data to understand how the quality of a drug 
substance and drug product changes with time under the inﬂuence of various 
environmental factors. Knowledge of the stability of molecule helps in selecting 
proper formulation and package as well as providing proper storage conditions and shelf 
life, which is essential for regulatory documentation. Forced degradation is a process 
that involves degradation of drug products and drug substances at conditions more 
severe than accelerated conditions and thus generates degradation products that can 
be studied to determine the stability of the molecule. The ICH guideline states that 
stress testing is intended to identify the likely degradation products which further 
helps in determination of the intrinsic stability of the molecule and establishing 
degradation pathways, and to validate the stability indicating procedures used.  
         Forced degradation studies provide knowledge about possible degradation 
pathways and degradation products of the active ingredients and help to elucidate 
the structure of the degradants. Degradation products generated from forced 
degradation studies are potential degradation products that may or may not be 
formed under relevant storage conditions but they assist in the developing stability 
indicating method. It is better to start degradation studies earlier in the drug 
development process to have sufficient time to gain more information about the 
stability of the molecule. This information will in turn help improve the formulation 
manufacturing process and determine the storage conditions. The aim of any 
strategy used for forced degradation is to produce the desired amount of degradation 
i.e., 5 – 20%. 
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OBJECTIVES OF FORCED DEGRADATION STUDIES  
 Forced degradation studies are carried out to achieve following purposes: 
 To establish degradation pathways of drug substances and drug products. 
 To differentiate degradation products that is related to drug products from 
 those that are generated from non-drug product in a formulation. 
 To elucidate the structure of degradation products. 
 To determine the intrinsic stability of a drug substance in a formulation. 
 To reveal the degradation mechanisms such as hydrolysis, oxidation, 
 thermolysis or photolysis of the drug substance and drug product. 
 To establish stability indicating nature of a developed method. 
 To understand the chemical properties of drug molecules. 
 To generate more stable formulations. 
 To produce a degradation profile similar to that of what would be observed 
 in a formal stability study under ICH conditions. 
 To solve stability related problems. 
 The ICH guidelines entitled “stability testing for new drug substance and 
products” (Q1A) requires that stress testing is carried out to elucidate the inherent 
stability characteristics of temperature, humidity, where appropriate, oxidative 
photolysis and susceptibility to hydrolysis. 
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ANALYTICAL METHOD VALIDATION 
 The work presented is validated by ICH guidelines Q2 (R1). The validation 
parameters being linearity, precision, accuracy, limit of detection, limit of 
quantification and robustness. 
Specificity: 
           Specificity is the ability of the method to accurately measure the analyte 
response in the presence of all the potential sample components. The response of 
the analyte in test mixtures containing the analyte and all the potential sample 
components is compared with the response of a solution containing only the analyte. 
Linearity:  
           The ability of the procedure to obtain results of the test directly proportional 
to the concentration of the analyte present in the sample. This will result in a linear 
relationship. This relationship is evaluated by statistical methods. To obtain 
linearity a minimum of 5 concentrations are needed. The parameters to be calculated 
are coefficient correlation, y intercept and slope. 
Range:  
  The range of an analytical method is the concentration over which 
acceptable accuracy, linearity, and precision are obtained in practice; the range is 
determined using data from the linearity and accuracy studies. 
Accuracy: 
 The accuracy of an analytical procedure expresses the closeness of 
agreement between the value which is accepted either as a conventional true value 
or an accepted reference value and the value found. 
Precision: 
  The precision of an analytical method is the amount of scatter in the results  
obtained from multiple analyses of a homogenous sample. It is determined at three 
levels. 
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a) Reproducibility 
 When the subject method is carried out by different analysts of different 
laboratories using different experimental conditions using the samples from same 
homogenous batch. 
 
b) Intermediate precision 
 It is determined by relating the results of a method within the same 
laboratory but different days, analysts, equipments and reagents. 
Limit of Detection (LOD) 
 The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be detected but not necessarily quantitated 
as an exact value.  
                                                    DL=3.3σ/S 
Limit of Quantitation (LOQ) 
 The quantitation limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be quantitatively determined with suitable 
precision and accuracy. The quantitation limit is a parameter of quantitative assays 
for low levels of compounds in sample matrices, and is used particularly for the 
determination of impurities and/or degradation products. 
                                                   DQ=10σ/S 
Robustness 
 The robustness of a method is its ability to remain unaffected by small 
changes in parameters such as percentage organic concentration and pH of mobile 
phase, concentration of buffer, temperature, injection volume and flow rate. 
Literature Review 
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LITERATURE REVIEW [10-15] 
 Vikas p. et al. (2016) developed a validated RP-HPLC  method for the 
determination of sofosbuvir in pure form. Separation of Sof was successfully 
achieved on a Hisil C18 (4.6 x 250mm, 5 μm) Waters or equivalent in an isocratic 
mode utilizing Phosphate Buffer (4.0 pH): Methanol (50:50%v/v) at a flow rate of 
0.8 mL /min and eluate was monitored at 262 nm, with a retention time of  
1.01 minutes. The method was validated and the response was found to be linear 
in the concentration range of 5 μg/mL to 30μg/mL. 
 
  Devilal.j. et al. (2016) described a RP- HPLC method for the 
determination of ledipasvir in bulk drug form. The procedure involved use of 
isocratic elution where the stationary phase was a ODS column (250 mm, 4.6 mm, 
5 μm), mobile phase 0.05% triflouroacetic acid in methanol and 0.05% 
triflouroacetic acid in acetonitrile (55:45). pH of the chromatographic system was 
maintained at 3.0, flow rate 1 ml/minute, eluent was monitored by PDA detector 
wavelength at 270 nm. Retention time was found to be 2.749 minutes, regression 
analysis shown the value of correlation coefficient 0.999. Value for limit of 
detection (LOD) was 1.064μgm/ml and limit of quantification (LOQ) was  
3.224 μg/ml. Linearity range was designed 15μg/ml to 300μg/ml for Ledipasvir. 
Accuracy study revealed percentage recovery 99.81%-100.10%. 
 
 Chenwei.P. et al. (2015) established a UPLC–MS/MS method for the 
Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat 
plasma and its application to a pharmacokinetic study. The analytes and the 
internal standard (diazepam) were separated on an Acquity UPLC BEH C18 
chromatography column (2.1 mm × 50 mm, 1.7 m) using gradient elution with a 
mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of  
0.4 mL/min. The detection was performed on a triple quadrupole tandem mass 
spectrometer. 
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 Nebsen.M. et al. (2016) has developed a LC–MS/MS method for 
Characterization of Forced Degradation Products of Sofosbuvir. However, it was 
stable under thermal and neutral hydrolysis stress conditions. Chromatographic 
separation of the drug from its degradation products was performed on Inertsil 
ODS-3 C18 (250mm × 4.6mm i.d., 5 μm) column using a methanol:water  
70:30 (v/v).  
 
 Elkady.F. et al. (2016) presented a LC-MS/MS Method for the 
Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in 
Human Plasma. The chromatographic separation of the three analytes was 
achieved within 2.8 min by an isocratic mobile phase consisting of 10 mM 
ammonium acetate, (pH 4.0) by acetic acid–acetonitrile–0.1% methanolic formic 
acid (12 + 25 + 63, v/v/v) flowing through a C18 Zorbax eclipse plus column  
(5 μm, 100 × 4.6 mm; Agilent). Linearity range was found to be 0.5 to 2500 and  
5 to 2100 ng/mL for sofosbuvir and ledipasvir, respectively. 
 
 Swain.D. et al.(2017) analysed a LC-QTOF-MS/MS and NMR methods 
for the forced degradation behaviour of ledipasvir. Identification of major 
degradation products using Ledipasvir degraded in hydrolytic (acid, alkaline and 
neutral) and oxidative stress conditions. The drug was found to be stable in 
thermal and photolytic conditions. The degradation products obtained were well 
separated using an HPLC C18 stationary phase (150 x 4.6 mm, 5 μ) and mobile 
phase composed of formic acid/acetonitrile in gradient elution mode. All the 
degradation products were characterized using tandem mass spectrometry with a 
time-of-flight analyser. 
 
 Aim& Objective 
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AIM AND OBJECTIVE [16-18] 
             Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) 
that primarily affects the liver. During the initial infection people often have no 
symptoms. Occasionally a fever, dark urine, abdominal pain and yellow tinged 
skin occurs. The virus persists in the liver 75%- 85%. 
             There is no vaccine currently against hepatitis C (however research in this 
area is ongoing). Antiviral medicines such as ledipasvir and sofosbuvir (cimivir-L 
tablet) can cure more than 95% of persons with hepatitis C, which is lifesaving 
drug. An estimated 143 million people (2%) worldwide are infected with hepatitis 
C as of 2015. It occurs most commonly in Africa and central and East Asia. Each 
year 3,99,000 people died for hepatitis C. 
 Literature survey revealed that no Spectrophotometric and HPTLC 
methods for the simultaneous estimation of Ledipasvir and Sofosbuvir. This 
combination tablet approved by FDA (10, Oct, 2014) which is a lifesaving drug. 
Which is not official in any of the pharmacopoeias and hence requires much more 
investigation. 
 Hence an attempt has been made to develop new, simple and economic 
and validated methods for the determination of Ledipasvir and Sofosbuvir in bulk 
and formulation 
Hence, the objectives of the present work is to develop a validated 
 UV-spectroscopic methods for the simultaneous estimation of ledipasvir 
 and sofosbuvir in bulk and formulation. 
 HPTLC method for the simultaneous determination of ledipasvir and                              
 sofosbuvir in bulk and formulation. 
 RP-HPLC method for the simultaneous determination of ledipasvir and 
 sofosbuvir in bulk and formulation. 
  
   Drug Profile 
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DRUG PROFILE [19, 20] 
Name                                :  Ledipasvir                
IUPAC Name                  :  methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2- 
                                           [(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)- 
                                           3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2- 
                                           yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H- 
                                           imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3- 
                                           methyl-1-oxobutan-2-yl]carbamate 
Empirical Formula           :  C49H54F2N8O6 
Structure Formula           : 
 
Molecular Weight            :   889.018 g/mol 
Description                       :   Slightly yellow solid 
Solubility                     :   Freely soluble in methanol. 
Bioavailability                  :  76% 
Storage                              :  25°C 
Category                           :  Antiviral agent (Hepatitis C virus)  
Dose                                   : 90mg 
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Name                                    :  Sofosbuvir                          
IUPAC Name                      :  propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4- 
                                                dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4- 
                                                methyloxolan-2-yl] methoxy- 
                                                phenoxyphosphoryl] amino]propanoate 
Empirical Formula             :  C22H29FN3O9P 
 
Structure Formula             : 
 
 
Molecular Weight              :  529.458 g/mol 
Description                         :  White to off-white solid 
Solubility                      :  Freely soluble in methanol. 
Bioavailability                   :   92% 
Storage                               :  30oC  
Category                            :  Antiviral agent (Hepatitis C virus)  
Dose                                   :  400mg 
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BRANDS AVAILABLE 
Brand names Strength(mg) Manufacturer 
Harvoni Ledipasvir 90/sofosbuvir 400 Mylan 
Hepcinat Ledipasvir 90/sofosbuvir 400 Natco 
Hepcvir-L Ledipasvir 90/sofosbuvir 400 Cipla 
Ledviclear Ledipasvir 90/sofosbuvir 400 Abbott 
Resof-L Ledipasvir 90/sofosbuvir 400 Dr.Reddy 
Cimivir-L* Ledipasvir 90/sofosbuvir 400 Biocon 
Sofocure-L Ledipasvir 90/sofosbuvir 400 Emcure 
Sofab-LP Ledipasvir 90/sofosbuvir 400 Ranbaxy 
Ledihep Ledipasvir 90/sofosbuvir 400 Zydus Cadila 
Ledifos Ledipasvir 90/sofosbuvir 400 Hetero 
Virpas Ledipasvir 90/sofosbuvir 400 Strides Shasun 
*Formulation used in present work 
Materials & Instruments 
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MATERIALS AND INSTRUMENTS 
Active Pharmaceutical Ingredient (API)  
          Ledipasvir and sofosbuvir were procured from sequent Labs Pvt. Ltd., 
Mangalore, India. 
Formulation 
    Cimivir-L tablet, Ledipasvir 90 / sofosbuvir 400 from Biocon 
Pharmaceuticals, Bangalore. 
 Chemicals and solvents used 
 Water- HPLC grade 
 Methanol HPLC grade, AR grade  
 Acetonitrile - HPLC grade  
 Formic acid- AR grade 
 Toluene- LR grade 
 Chloroform- LR grade 
 Sodium hydroxide- LR grade 
 Hydrochloric acid- AR grade 
 Hydrogen peroxide 6 %-LR grade  
 Hydrogen peroxide 30 %-LR grade  
 Ammonium acetate 
 Triethyl amine 
 Ammonia 25% 
 Ethyl acetate 
 Hexane 
 Orthophosphoric acid 
All the above chemicals and solvents were supplied by S.D. Fine 
chemicals Ltd., India, Sigma-aldrich Chemicals Pvt. Ltd., Maharashtra, India and 
Ranbaxy chemicals Ltd., New Delhi, India. 
Materials & Instruments 
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MATERIALS USED 
 Pre-coated silica gel 60F254 on aluminium sheets were procured from 
Merck, Germany. 
 Hibar, C18 column (250mm×4.0mm, 5μm) column was obtained from 
Merck Pvt. Ltd., Mumbai. 
INSTRUMENTS USED 
1.  Shimadzu digital electronics balance 
2.         Systronics Pvt. Limited, India, pH meter 
3.   Jasco V-630 UV/ Vis- spectrophotometer 
4.   Camag HPTLC system (with TLC Scanner-3, Win CATS software and 
Linomat 5 as application device) 
5.  Shimadzu HPLC prominence i LC-2030 liquid chromatography system 
with UV-VISIBLE detector and auto sampler injector. Chromatogram 
were recorded and integrated on PC installed with lab solutions 
chromatographic sofotware. 
6.         Shimadzu HPLC system with SPD-M10 A VP system PDA with 20µl 
fixed volume manual injector and LC-MS solution software. 
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DEVELOPMENT OF VALIDATED UV-SPECTROSCOPIC METHODS 
FOR THE SIMULTANEOUS ESTIMATION OF LEDIPASVIR AND 
SOFOSBUVIR IN BULK AND FORMULATION 
 Ledipasvir and sofosbuvir is having π electron in its structure and hence 
absorbs electromagnetic radiation. UV- spectroscopic methods are simple and 
suitable to determine ledipasvir and sofosbuviri in pharmaceutical formulation. 
SELECTION OF PARAMETERS FOR METHOD DEVELOPMENT: 
1. SELECTION OF SOLVENT 
 The solubility of ledipasvir and sofosbuvir were checked in various 
solvents like methanol and acetone, etc. The one which showed good spectrum 
and good stability was selected as solvent of choice for the determination of 
ledipasvir and sofosbuvir. 
2. PREPARATION OF STOCK SOLUTION 
         Ten milligram of pure drug ledipasvir and sofosbuvir were weighed, 
transferred and made up to 10 ml with methanol in a standard flask previously 
rinsed with methanol to get concentration of 1000 µg/ml. From the stock 1ml was 
diluted to 10 ml, to get a concentration of 100µg/ml. Further, the working 
standard solutions were prepared from 100µg/ml. The prepared stock solution was 
used for further studies. 
3. SELECTION OF WAVELENGTH 
          After selection of suitable solvent for ledipasvir and sofosbuvir and 
preparation of stock solution, a solution containing 20µg/ml of ledipasvir and 
sofosbuvir was prepared and scanned in the range of   200 to 400 nm against 
methanol as blank. This was known as normal spectrum. Further this was 
derivatised to obtain second order derivative spectrum. 
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VALIDATION 
LINEARITY AND RANGE 
 From the stock solution containing 100µg/ml of ledipasvir about 1 to 4ml  
and sofosbuvir 1 to 7ml were transferred into 10ml volumetric flasks and the 
working standards were prepared by making up to the volume using methanol to 
get concentration of ledipasvir about 10-40µg/ml and sofosbuvir about  
10-70µg/ml. The absorbances were noted for all the standard solutions of 
ledipasvir and sofosbuvir at the selected wavelength. Standards were scanned in 
the wavelength range of 200 nm – 400 nm. The linear graph was plotted between 
concentrations (µg/ml) versus absorbance. Then it is derivatised to second order 
derivative and the amplitudes (mm) were measured at ledipasvir 333nm and 
sofosbuvir 261nm. The respective calibration graphs were prepared by plotting 
concentration against corresponding amplitude.  
PRECISION 
 Precision of the method was determined by repeating the assay six times. 
Repeatability was carried out using 20µg/ml for both drugs normal and second 
order derivative methods. To study intraday precision, it was repeated 3 times on 
the same day using 20 and 30 µg/ml for both drugs and % RSD was calculated. 
Similarly the interday precision was performed by repeating the above procedure 
on different days and average of % RSD was calculated. Precision studies were 
carried out for both the methods. 
RECOVERY STUDIES 
          To study the accuracy of the proposed method, standard addition 
procedure was adopted. To a pre - analysed sample solutions a known quantity of 
standard ledipasvir and sofosbuvir were added at 50%, 100% and 150% levels. 
Recovery was calculated from the ratio of difference between the amount of drug 
found after the addition of standard drug and amount of analyte present in 
preanalysed formulation to that of the standard ledipasvir and sofosbuvir added to 
the formulation.  
Experimental Section UV 
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LOD AND LOQ: 
 From the limit of detection and limit of quantification the sensitivity of the 
method was determined. The LOD and LOQ were calculated using the equation, 
 LOD = 3.3 × σ/S 
 LOQ = 10 × σ/S 
 Where, σ is the standard deviation of y intercept of regression line, & S is 
slope of calibration curve. 
STABILITY STUDIES: 
 When the prepared solution is exposed to atmosphere, the analytes are 
likely to decompose; hence it is necessary to conduct stability studies. Stability of 
the analyte in methanol was studied, at room temperature for 8 hours and in 
refrigeration for 4 days and absorbance was compared with the absorbance of 
freshly prepared solution. 
APPLICATION OF THE PROPOSED METHODS FOR ANALYSIS OF 
FORMULATION: 
 Cimivir-L was assayed by Zero and second order UV spectrophotometric 
methods. Twenty tablets were weighed and finely powdered. The powder mass 
equivalent to 5mg of ledipasvir and sofosbuvir were accurately weighed and 
transferred to 50ml standard flask containing 10ml of methanol and made up to 
volume with the same and sonicated for dissolution for five minutes. The solution 
was filtered using whatman(no.1) filter paper. Suitable dilutions were made with 
methanol to get the concentrations of 10µg/ml for ledipasvir and 44µg/ml for 
sofosbuvir. Normal and second order derivative were recorded against methanol 
as blank. The content of cimivir-L was calculated using respective calibration 
graph. 
                                                              Experimental Section HPTLC 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR THE 
SIMULTANEOUS DETERMINATION OF LEDIPASVIR AND 
SOFOSBUVIR IN BULK AND FORMULATION 
 The experimental work consists of optimization of chromatographic 
conditions development and validation of HPTLC method of ledipasvir and 
sofosbuvir. 
1.   Selection of plate  
         A pre-coated silica gel G60 F254 coated on aluminum sheet was selected for the 
study. 
2.  Selection of solvent 
          Drug should be soluble in the solvent used. 
           Drug should show stability in the solvent used. 
           Solvent should be volatile. 
3.  Selection of wavelength  
          The sensitivity of HPTLC method depends upon the proper selection of 
wavelength for UV detection. An ideal wavelength is that the overlay that give 
maximum absorbance and good response for the drug to be selected at the lower 
concentration is to be selected. The UV spectrum of ledipasvir and sofosbuvir were 
scanned 200-400nm in HPTLC scanner and the isobestic point was selected for the 
further study. 
4.  Optimization of mobile phase system 
             Initially different solvent systems were tried and A solvent system with 
compact spots and good separation has been selected for the study. 
5.  Selection of ratio of mobile phase system  
                Different ratios hexane : ethyl acetate : methanol (3:5:2, 8:2:2, 5:3:2, 
v/v/v etc) were tried along with few drops of ammoniato get dense compact spots 
with good resolution.  
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6. Optimization of chamber saturation  
            After selection of mobile phase ratio the twin trough chamber was saturated 
for 15 minutes to 25 minutes using mobile phase system fix the chamber saturation 
time.  
7.  Preparation of stock solutions 
   The mixed stock solution of  ledipasvir (100µg/ml) and sofosbuvir 
(440µg/ml) was prepared using methanol in 10ml volumetric flask. 
VALIDATION OF THE METHOD: 
 The developed method was validated as per ICH guidelines. The validation 
of the method was carried out in terms of linearity, accuracy, precision, 
repeatability, LOD and LOQ. 
LINEARITY AND RANGE:  
 The linear response for the mixture (ledipasvir and sofosbuvir) was assessed 
by spotting different volume of mixed stock solution from 1 to 7 µL on TLC plate. 
ACCURACY: 
 The accuracy study was conducted at 50, 100 and 150% level for the pre-
analysed samples by standard addition method. 
PRECISION: 
 Precision of the method was studied by 
 Intra-day precision  
 Inter-day precision  
 Repeatability precision 
 Repeatability of sample measurement 
 Repeatability of sample application 
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Intra-day precision: 
 Intra-day precision was studied by carrying out the analysis of the standard 
drug of two different concentrations for three times on the same day and %RSD 
was calculated. 
Inter-day precision:  
            Inter-day precision was studied by carrying out the analysis of the standard 
drug of two different concentrations for three different days over a period of one 
week and %RSD was calculated. 
REPEATABILITY: 
Repeatability of sample measurement: 
       Repeatability of measurement was determined by spotting 300ng/spot of 
ledipasvir and 1320ng/spot of sofosbuvir drug solution on a pre-coated TLC plate 
and developed the plate was scanned six times and %RSD was calculated. 
Repeatability of sample application: 
      Repeatability of sample application was carried by spotting 6 times of 2µl 
of drug solution on pre-coated TLC plate followed by development of plate and 
%RSD was calculated. 
LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTIFICATION 
(LOQ): 
       The lowest concentration detected (LOD) and lowest concentration 
quantified (LOQ) were estimated from the set of five calibration curves used to 
determine method linearity. 
LOD   = 3.3×σ/S and LOQ = 10×σ/S 
Where, σ = the standard deviation of y intercepts of regression lines 
 S   = the slope of the calibration curve 
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ROBUSTNESS: 
 The effect of deliberate variations on method parameters like the 
composition of the mobile phase saturation time, development distance spot 
scanning time interval, wavelength scan time from spotting to chromatography and 
mobile phase volume was evaluated.  
SPECIFICITY 
            The peak purity of ledipasvir and sofosbuvir was assessed by comparing its 
respective spectra at the three different levels, that is, peak start (S), peak apex (M) 
and peak end (E) positions of the spot. 
STABILITY STUDIES: 
 When the developed chromatographic plate is exposed to atmosphere, the 
analytes are likely to decomposed. It is necessary to study the stability of drug on 
plate. It was studied by scanning the plate at different time interval and peak areas 
were compared with the peak area of freshly scanned plate. The developed plate 
was found to be stable for about 24 hours. 
ANALYSIS OF FORMULATION 
 To determine the amount of ledipasvir and sofosbuvir in tablet dosage form 
(label claim 90& 400mg per tablet respectively) 20 tablets were weighed, their 
average weight was determined, and they were finely powdered. An accurately 
weighed powder sample equivalent to 9mg of ledipasvir or 40mg of sofosbuvir was 
transferred into a 100ml volumetric flask then added 10ml methanol, followed by 
sonication for 10 min and further dilution was made up to the mark with methanol. 
The resulting solution was filtered through whatman filter paper (No.1) and two 
microliters of the filtered solution (180ng/spot of ledipasvir & 800ng/spot of 
sofosbuvir) was applied on the TLC plate followed by development and scanning 
as per optimized chromatographic conditions. 
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STRESS STUDIES 
Forced degradation studies for Ledipasvir and Sofosbuvir 
 For conducting the forced degradation studies, four samples were taken viz., 
the blank solution stored under normal conditions, the blank subjected to stress in 
the similar manner as the drug solution, zero time analyte solution which was stored 
under normal and the sample subjected to stress treatment. The study was conducted 
separately for ledipasvir and sofosbuvir individually and also for combination. 
Acid Hydrolysis: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separately. To this 10 ml of 0.1M hydrochloric 
acid was added and made up to 25ml with methanol. This solution was refluxed for 
5 hours at 80˚C. Further 2.5 ml was made up to 10ml (1000µg/ml) for ledipasvir 
and sofosbuvir individually and also for mixture. 
Alkaline Hydrolysis: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separately. To this 10 ml of 0.1M sodium 
hydroxide was added and made up to 25ml with methanol. This solution was 
refluxed for 5 hours at 80˚C. Further 2.5 ml was made up to 10ml (1000µg/ml) for 
ledipasvir and sofosbuvir individually and also for mixture. 
Neutral hydrolysis: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separately. To this 10 ml of water was added 
separately and made up to 25 ml methanol. This solution was refluxed for 5 hours 
at 80˚C. Further 2.5 ml was made up to 10ml (1000µg/ml) for ledipasvir and 
sofosbuvir individually and also for mixture. 
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Oxidative Degradation: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separately. To this 10 ml of 6% hydrogen 
peroxide was added separately and made up to 25ml with methanol. Further 1 ml 
was withdrawn 1 hour once for about 5 hours and Further 2.5 ml was made up to 
10ml (1000µg/ml) for ledipasvir and sofosbuvir individually and also for mixture. 
Thermal degradation: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed and 
transferred to a petri dish separately. It was then placed in hot air oven at 80ºC for 
5 hours then dissolved and made up to 25 ml with methanol. Further 2.5 ml was 
taken and made up to 10ml (1000µg/ml) for ledipasvir and sofosbuvir individually 
and also for mixture. 
Photolytic degradation: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed and 
transferred to a petri dish. It was then exposed to sunlight for about 5 hours. The 
drug solution was prepared using methanol. Further 2.5 ml was taken and made up 
to 10ml (1000µg/ml) for ledipasvir and sofosbuvir individually and also for 
mixture. 
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DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE 
SIMULTANEOUS DETERMINATION OF LEDIPASVIR AND 
SOFOSBUVIR IN BULK AND FORMULATION 
1.  Chromatographic method for separation: 
       The drug Ledipasvir and Sofosbuvir is polar in nature, RP-HPLC method 
was selected as separation technique. 
2.  Selection of solvent: 
      The drugs are soluble in acetonitrile and also showed good stability. Hence 
methanol was selected as the solvent. 
3.  Selection of Detection wavelength: 
       Good analytical separation can be obtained only by careful selection of 
wavelength for the detection. This choice requires knowledge of the UV spectrum 
of the sample component. A UV spectrum of ledipasvir and sofosbuvir was 
recorded in acetonitrile and the overlay have shown acceptable absorbance at 
254nm for both drugs and it was selected for the study. 
OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS  
Selection of mobile phase: 
            Here different mobile phase with different ratios were tried like water: 
methanol, water: acetonitrile and orthophosphoric acid buffer and acetonitrile.  
Selection of strength of acetic acid: 
            Different strengths of formic acid such as 0.5%, 1% and 1.5% were tried. 
Good peak characteristics was observed for strength of 1% orthophosphoric acid 
and hence selected. 
. 
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Selection of pH of orthophosphoric acid: 
            The pH which gave the good peak characteristic was selected for the further 
study.  
Selection of mobile phase ratio: 
 Different ratio of 1% orthophosphoric acid: acetonitrile tried from which a 
ratio of 30:70% v/v gave good resolution and satisfactory peak shapes. 
Selection of flow rate: 
 Keeping all other parameters of mobile phase system constant, the 
chromatograms were recorded different flow rates like 0.7, 0.8, 0.9, 1 and 1.1 
ml/min were tried. A flow rate which gave good symmetrical peaks and good 
resolution.  
Chromatographic development procedure: 
 The HPLC system was stabilized for 60min, by passing mobile phase and 
detector was set as 254nm and flow rate of 0.8ml/min was maintained to get a steady 
baseline. One blank followed by six replicate of a single standard solution were 
injected to check the system suitability. 
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VALIDATION OF THE METHOD  
 The developed HPLC method was validated according to ICH guidelines in 
terms of linearity, accuracy, precision, specificity, robustness and LOD and LOQ. 
LINEARITY AND RANGE: 
 The mixed standard stock solution (100µg/ml of ledipasvir and 100µg/ml of 
sofosbuvir) was further diluted to get ledipasvir and sofosbuvir concentration in the 
range of 1-10µg/ml and 1-10µg/ml respectively. Linearity of the method was 
studied by injecting ten concentration of the drug prepared in the mobile phase in 
triplicate into the LC system keeping the injection volume constant,  The  peak areas 
were plotted against the corresponding concentration to obtain the calibration 
graphs.  
ACCURACY: 
 Accuracy of the method was carried out by applying the method to drug 
sample ( ledipasvir and sofosbuvir combination tablet) to which known amount of 
ledipasvir and sofosbuvir standard powder corresponding to 50, 100 and 150% of 
label claim had been added (standard addition method) mixed and the powder was 
extracted and analyzed by running chromatogram in optimized mobile phase. 
PRECISION: 
 The precision of the method was verified by intraday, interday and 
repeatability precision studies. 
 Intra-day precision 
 Inter-day precision  
 Repeatability  
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Intra-day precision: 
 Intraday precision was determined by injecting standard solutions in 
between linearity range (4, 8µg/ml for ledipasvir and 4, 8µg/ml for sofosbuvir) were 
injected three times on the same day and % RSD was calculated. 
Inter-day precision: 
 Inter-day precision was determined by injecting standard solutions in 
between linearity range (4, 8µg/ml for ledipasvir and 4, 8µg/ml for sofosbuvir) were 
injected for three days and % RSD was calculated. 
Repeatability: 
 Repeatability studies were performed by analysis of different concentration 
4µg/ml ledipasvir and 4µg/ml of sofosbuvir six times on the same day and %RSD 
was calculated. 
LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTITATION (LOQ): 
 The lowest concentration detected (LOD) and lowest concentration 
quantified (LOQ) were estimated from the set of five calibration curves used to 
determine method linearity. 
LOD = 3.3×σ/S  
         LOQ = 10×σ/S 
Where, σ = the standard deviation of y intercepts of regression lines 
 S   = the slope of the calibration curve 
SPECIFICITY: 
 The specificity of the method towards the drug was established through 
study of resolution factor of the drug peak from the nearest resolving peak. The 
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peak purity of ledipasvir and sofosbuvir were determined by comparing the 
spectrum at three different regions of the spot i.e. peak start (S), peak apex (M) and 
peak end (E). Effect of excipients of formulation was studied for whether it 
interfered with the assay.         
ROBUSTNESS: 
        To evaluate robustness of a HPLC method, few parameters were 
deliberately varied. The parameters included variation of flow rate, percentage of 
acetonitrile in the mobile phase and solvents. The response factors like retention 
time, resolution, asymmetric factor for these changed conditions were noted. 
STABILITY OF SOLUTION: 
       The standard solution of ledipasvir and sofosbuvir kept under room 
temperature. It was injected periodically. Stability was studied by looking for any 
change in retention time, resolution and peak shape, when compared to 
chromatogram of freshly prepared solution. The solution was stable 24hrs under 
room temperature. 
SYSTEM SUITABILITY STUDIES: 
       The system suitability parameters like peak area, tailing factor, theoretical 
plate count, and resolution and retention time were calculated from the standard 
chromatograms. 
ANALYSIS OF A MARKETED FORMULATION: 
          To determine the amount of ledipasvir and sofosbuvir in tablet dosage form 
(label claim 90& 400mg per tablet respectively) 20 tablets were weighed, their 
average weight was determined, and they were finely powdered. An accurately 
weighed powder sample equivalent to 9mg of ledipasvir and 40mg of sofosbuvir 
was transferred into a 100ml volumetric flask then added 10ml acetonitrile, 
followed by sonication for 10 min and further dilution up to the mark with 
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acetonitrile. The resulting solution was filtered through whatman filter paper (No.1) 
and using syringe 0.45µm. The above stock solution was further diluted to get 
sample solution of 0.9µg/ml of ledipasvir and 4µg/ml of sofosbuvir respectively. A 
20µl volume of sample solution was injected into HPLC, six times, under the 
conditions described above. The peak areas were measured at 254nm.  
STRESS STUDIES 
Forced degradation studies for Ledipasvir and sofosbuvir: 
 For conducting the forced degradation studies, four samples were taken viz., 
the blank solution stored under normal conditions, the blank subjected to stress in 
the similar manner as the drug solution, zero time analyte solution which was stored 
under normal and the sample subjected to stress treatment. The study was conducted 
separately for ledipasvir and sofosbuvir individually and also for combination. 
 
Acid Hydrolysis: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separately. To this 10 ml of 0.1M hydrochloric 
acid was added and made up to 25ml with acetonitrile. These solution was refluxed 
for 5 hours at 80˚C. Further 0.25 ml was made up to 100ml (10µg/ml) for ledipasvir 
and sofosbuvir individually and also for mixture.  
 
Alkaline Hydrolysis: 
             Hundred milligram of ledipasvir and sofosbuvir was weighed accurately 
and transferred into 25ml standard flasks separetely. To this 10 ml of 0.1M sodium 
hydroxide was added and made up to 25ml with acetonitrile. This solution was 
refluxed for 4 hours at 80˚C. Further 0.25 ml was made up to 100ml (10µg/ml) for 
ledipasvir and sofosbuvir individually and also for mixture. 
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Neutral hydrolysis: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separetely. To this 10 ml of water was added 
separately and made up to 25 ml acetonitrile. This solution was refluxed for 4 hours 
at 80˚C. Further 0.25 ml was made up to 100ml (10µg/ml) for ledipasvir and 
sofosbuvir individually and also for mixture.  
Oxidative Degradation: 
 Hundred milligram of ledipasvir and sofosbuvir was weighed accurately and 
transferred into 25ml standard flasks separately. To this 10 ml of 6% hydrogen 
peroxide was added separately and made up to 25ml with acetonitrile. Further 1 ml 
was withdrawn 1 hour once for about 5 hours and Further 0.25 ml was made up to 
100ml (10µg/ml) for ledipasvir and sofosbuvir individually and also for mixture. 
Thermal degradation: 
            Hundred milligram of ledipasvirand sofosbuvir was weighed and transferred 
to a petri dish separately. It was then placed in hot air oven at 80ºC for 5 hours then 
dissolved and made up to 25 ml with acetonitrile. Further 0.25 ml was made up to 
100ml (10µg/ml) for ledipasvir and sofosbuvir individually and also for mixture.  
Photolytic degradation: 
           Hundred milligram of ledipasvir and sofosbuvir was weighed and transferred 
to a petri dish separately. It was then exposed to sunlight for about 5 hours. The 
drug solution was prepared using acetonitrile. Further 0.25 ml was made up to 
100ml (10µg/ml) for ledipasvir and sofosbuvir individually and also for mixture. 
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DEVELOPMENT OF VALIDATED UV-SPECTROSCOPIC METHODS 
FOR THE  ESTIMATION OF LEDIPASVIR AND SOFOSBUVIR IN 
BULK AND FORMULATION 
         Ledipasvir and sofosbuvir possess chromophoric groups like benzene 
extended to carbonyl (=c=o) and alkene (=c=c) functional groups. Amide (-NH) 
and hydroxyl(-OH) groups as auxochrome which contribute into strong UV 
absorption of the molecule. This character is used for the determination of 
ledipasvir and sofosbuvir by UV spectroscopic methods. 
        Ideal solvent is the one which completely solublize the drug and should 
maintain good stability of the drug in solution. Initially solvents like acetone and 
methanol were tried, among these spectrum of ledipasvir and sofosbuvir was not 
good and smooth but, methanol gave a good absorption spectrum with acceptable 
stability and sensitivity. Hence methanol was selected as solvent of choice for 
further studies. The overlay spectra is shown in the Figure 1a and 1b. 
Figure 1a: Overlay spectra of solvent selection of Ledipasvir 
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Figure 1b: Overlay spectra of solvent selection of Sofosbuvir
 
        An ideal wavelength is the one that gives good response with maximum 
absorbance for the both drug to be detected. The normal UV spectrum of 
ledipasvir 333nm and sofosbuvir 261nm were selected as detection wavelength 
because the linear response was very good with maximum acceptable absorbance, 
but wavelength less than 215nm is not commonly used due to solvent interference. 
But the derivatised normal also spectrum showed the Ȝmax at 333nm for ledipasvir 
and 261nm for sofosbuvir which was used for further studies. 
 The normal spectrum and the derivative spectrum of both drugs for 
20ȝg/ml are shown in the figure 2a & 2b and 3a & 3b, respectively. 
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Figure 2a:  Normal spectrum of Ledipasvir (20μg/ml) 
 
Figure 2b:  Second order derivative spectrum of Ledipasvir (20μg/ml) 
 
333nm 
333nm 
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Figure 3a:  Normal spectrum of Sofosbuvir (20μg/ml) 
 
 
Figure 3b:  Second order derivative spectrum of Sofosbuvir (20μg/ml) 
 
 
261nm 
261nm 
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VALIDATION PARAMETERS  
Linearity and range: 
        The linear regression analysis showed good correlation coefficient and 
good linear relationship over concentration range of ledipasvir 10– 40µg/ml and 
sofosbuvir 10- 70 µg/ml, Overlay of normal spectra were shown in figure 4a & 4b 
and calibration graph was shown in figure 5a & 5b and the values are tabulated in 
table 1a & 1b, respectively. 
Figure 4a: Overlay of normal spectrum of Ledipasvir 
 
  
333nm 
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Figure 4b: Overlay of normal spectrum of Sofosbuvir 
 
Table 1a: Calibration data for normal spectrum of Ledipasvir 
S.No Concentration (μg/ml) Absorbance 
1. 10 0.2422 
2. 15 0.3533 
3. 20 0.4853 
4. 25 0.5346 
5. 30 0.7491 
6. 35 0.8756 
7. 40 0.9859 
 
 
 
261nm 
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Figure 5a: Linear graph of Ledipasvir (10-40μg/ml) 
 
 
Table 1b: Calibration data for normal spectrum of sofosbuvir 
S.No Concentration (μg/ml) Absorbance 
1. 10 0.2222 
2. 20 0.3985 
3. 30 0.4404 
4. 40 0.7211 
5. 50 0.9096 
6. 60 1.0913 
7. 70 1.2395 
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Figure 5b: Linear graph of Sofosbuuvir (10-70μg/ml) 
 
 Similarly, the normal spectrum was converted to second order derivative, 
and the corresponding overlay and linear graph was shown in the figure 6a & 6b 
and 7a & 7b and data are shown in table 2a & 2b. 
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Figure 6a: Second order derivative spectrum of Ledipasvir 
 
Figure 6b: Second order derivative spectrum of Sofosbuvir 
 
 
333nm 
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Table 2a: Calibration data for Second order derivative of  
Ledipasvir(10-40 µg/ml) 
S.No Concentration(μg/ml) Amplitude(mm) 
1. 10 8 
2. 15 13 
3. 20 16 
4. 25 19 
5. 30 24 
6. 35 28 
7. 40 32 
 
Figure 7a: Linear graph for second order derivative of Ledipasvir 
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Table 2b: Calibration data for Second order derivative of  
Sofosbuvir (10-70 µg/ml) 
S.No Concentration(μg/ml) Amplitude(mm) 
1. 10 5 
2. 20 10 
3. 30 13 
4. 40 19 
5. 50 24 
6. 60 29 
7. 70 33 
 
 
Figure 7b: Linear graph for second order derivative of Sofosbuvir 
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Precision: 
 For both zero and second order derivative methods %RSD  values were 
less than 2 for repeatability, intraday precision, and interday precision, which 
indicated the methods were more precise and the values are listed in the table 3a 
& 3b to 5a & 5b. 
Table 3a:  Precision studies of Ledipasvir 
(i)Repeatability (Normal method) 
Concentration taken 
(μg/ml) Absorbance %RSD* 
30 
 
0.7490 
0.649 
0.7432 
0.7461 
0.7472 
0.7371 
0.7385 
* Average six determination 
(ii)Repeatability (second order) 
Concentration 
taken(μg/ml) Amplitude(mm) %RSD* 
 
30 
24 
0.022 
24 
24 
25 
25 
25 
* Average six determination 
 
Results & Discussion - UV 
 
 
 
Department of Pharmaceutical Analysis   56 
 
 
Table 3b:  Precision studies of Sofosbuvir 
(i)Repeatability (Normal method) 
Concentration taken 
(μg/ml) Absorbance %RSD* 
 
30 
 
0.4404 
0.880 
0.4415 
0.4412 
0.4426 
0.4439 
0.4329 
* Average six determination 
(ii)Repeatability (second order) 
Concentration 
taken(μg/ml) Amplitude(mm) %RSD* 
 
30 
13 
0.038 
14 
13 
13 
13 
14 
* Average six determination 
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Table 4a: Intraday precision of Ledipasvir 
(i)Normal method 
Concentration taken 
(μg/ml) Absorbance %RSD* 
20 
0.4892 
0.971 0.4801 
0.4826 
 
30 
 
0.7495 
0.634 0.7401 
0.7456 
*Average of three determination 
(ii) Intraday precision (Second order derivative) 
Concentration taken(μg/ml) Amplitude(mm) %RSD* 
 
20 
 
16 
0.035 16 
17 
30 
24 
0.023 25 
25 
*Average of three determination 
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                              Table 4b: Intraday precision of Sofosbuvir 
i. Normal  method 
Concentration taken (μg/ml) Absorbance %RSD* 
20 
0.3984 
0.824 0.3919 
0.3956 
30 
0.4402 
0.643 0.4459 
0.4431 
*Average of three determination 
ii. Intraday precision (Second order derivative) 
Concentration taken (μg/ml) Amplitude(mm) %RSD* 
20 
10 
0.043 11 
10 
30 
13 
0.043 13 
14 
*Average of three determination   
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Table 5a: Interday Precision of ledipasvir 
i. Normal method 
*Average of three determination 
ii. Interday precision (second order derivative) 
Concentration taken(μg/ml) Amplitude(mm) %RSD 
20 
16 
0.034 17 
17 
30 
24 
0.024 23 
23 
*Average of three determination 
 
 
 
 
Concentration taken(μg/ml) Absorbance %RSD* 
20 
0.4806 
1.841 0.4896 
0.4719 
30 
0.7495 
0.693 0.7418 
0.7397 
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Table 5b: Inter day Precision of Sofosbuvir 
i. Normal method 
*Average of three determination 
ii. Interday precision (second order derivative) 
Concentration taken(μg/ml) Amplitude(mm) %RSD* 
20 
10 
0.056 11 
10 
30 
14 
0.042 14 
13 
*Average of three determination 
Recovery: 
 In order to demonstrate the suitability, reliability, accuracy and 
applicability of the proposed methods, recovery studies were conducted for pre – 
analysed sample formulation by standard addition method. The percentage 
recovery was close to 100 proved that the methods are highly accurate. The results 
are given in the table 6a &6b. 
Concentration taken(μg/ml) Absorbance %RSD* 
20 
0.3984 
1.355 0.3907 
0.3882 
30 
0.4402 
0.500 0.4432 
0.4389 
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Table 6a: Recovery study for ledipasvir 
i. Normal method 
Level % Recovery %RSD* 
50% 99.41% 0.01 
100% 98.37% 0.12 
150% 98.15% 0.14 
* Average of six determination 
 
ii. Second order 
Level % Recovery %RSD* 
50% 101.84% 0.13 
100% 103.71% 0.38 
150% 101.65% 0.15 
* Average of six determination 
 
Table 6b: Recovery study for Sofosbuvir 
i. Normal method 
Level % Recovery %RSD* 
50% 97.38% 1.21 
100% 98.15% 0.35 
150% 97.21% 0.04 
* Average of six determination 
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ii. Second order 
Level % Recovery %RSD* 
50% 101.86% 0.84 
100% 99.20% 0.15 
150% 102.79% 0.95 
*Average of six determination 
LOD & LOQ: 
              The sensitivity of the method is proved by limit of detection and limit of 
quantification that were calculated from the equation . Ledopasvir LOD and LOQ 
were found to be  0.24246 µg/ml and 0.7347µg/ml for normal and 0.004454µg/ml 
and   0.0134µg/ml for second order derivative. sofosbuvir LOD and LOQ were 
found to be  0.24246 µg/ml and 0.7347µg/ml for normal and 0.004454µg/ml and   
0.0134µg/ml for second order derivative. 
Stability studies: 
               Stability of ledipasvir and sofosbuvir in solution was about 6hours in 
normal room temperature and about 3 days at refrigeration that was shown in table 
7a & 7b and 8a & 8b. 
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Table 7a: Stability of the solution at normal room temperature Ledipasvir 
Concentration (μg/ml) Time (hours) Absorbance 
15 
1 0.3565 
2 0.3548 
3 0.3536 
4 0.3528 
5 0.3564 
6 0.3514 
7 0.3426 
8 0.3415 
 
Table 7b:  Stability of the solution at refrigeration Ledipasvir 
Concentration (μg/ml) Time (hours) Absorbance 
15 
1 0.3566 
2 0.3549 
3 0.3568 
4 0.3578 
5 0.3548 
6 0.3565 
7 0.3545 
8 0.3515 
24 0.3526 
48 0.3545 
72 0.3512 
96 0.3015 
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Table 8a: Stability of the solution at normal room temperature  Sofosbuvir 
Concentration (μg/ml) Time (hours) Absorbance 
20 
1 0.3984 
2 0.3982 
3 0.3978 
4 0.3961 
5 0.3961 
6 0.3936 
7 0.3611 
8 0.3548 
 
Table 8b:  Stability of the solution at refrigeration sofosbuvir 
Concentration (μg/ml) Time (hours) Absorbance 
20 
1 0.3956 
2 0.3945 
3 0.3925 
4 0.3912 
5 0.3915 
6 0.3910 
7 0.3909 
8 0.3905 
24 0.3901 
48 0.3900 
72 0.3255 
96 0.3122 
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 The proposed method was successfully applied to formulation. The 
spectrum of analysis of formulation both normal and second order was shown in 
figure 8 and 9.The estimated amount and % label claim are shown in table 11.   
Figure 8:  Normal spectrum of formulation of  
ledipasvir(9μg/ml) and sofosbuvir(40μg/ml) 
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Figure 9: Second order derivative spectrum of formulation of 
Ledipasvir(9mcg/ml) & Sofosbuvir (40mcg/ml) 
 
Table 11: Analysis of formulation 
                                    i. Simultaneous equation method 
Methods 
                   Cimivir-L 
           Amount of drug(mg/tab) % Label 
Claim 
% RSD* 
Labelled Estimated 
Ledipasvir         90            89.21       99.12%   0.28 
Sofosbuvir        400           398.43       99.60%   0.94 
*Average of six observation 
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ii. Second order derivative 
Methods 
Cimivir-L 
Amount of drug(mg/tab) % Label 
Claim 
% RSD* 
Labelled Estimated 
Ledipasvir 90 92.02 102.24% 0.54 
Sofosbuvir 400 398.97 99.74% 0.74 
*Average of six observation 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR THE 
SIMULTANEOUS DETERMINATION OF LEDIPASVIR AND 
SOFOSBUVIR IN BULK AND FORMULATION 
 
 The pre – coated silica gel G60F254 in aluminium sheet was selected as 
stationary phase. In this acetonitrile was the solvent selected for the study because 
it completely solubilise the drug and show good stability of the drug in its solution 
form with acceptable volatile nature. 
 
        An ideal wavelength is the one that gives good response with maximum 
absorbance for the both drug to be detected. The spectra was recorded for the both 
ledipasvir and sofosbuvir on TLC scanner. From the spectra the isobestic point  
(288nm) was selected for further study. Fig 10 
Figure10:  Overlay spectrum of ledipasvir and sofosbuvir 
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Solvent system selection 
Mobile phase system Observation 
Toluene : ethanol (7:3, v/v) Poor separation 
Toluene: ACN: Ethyl acetate(6:2:2, 
v/v/v) Spot did not separate 
Toluene : Ethyl acetate (7:3,v/v) Spot not developed 
Toluene : Butyl acetate : methanol 
(7:2:1,v/v/v) Poor separation 
Hexane: Ethyl acetate : methanol 
(5:3:2,v/v/v) Good separation 
 Among these systems, system consisting of hexane : ethyl acetate : 
methanol was selected.  
 Fixed Experimental Conditions 
 Stationary phase       :  Pre-coated silica gel G60F254 on aluminum sheets 
 Mobile phase                    : Hexane : Ethyl acetate : methanol (4:5:1, v/v/v), 
                                               few drops  ammonia  
 Development chamber :  Camag twin trough glass chamber 
 Separation technique       : Ascending development 
 Chamber saturation time  :  15 min 
 Plate migration distance   : 80mm 
 Band width                       :  6mm 
 Slit dimension   :  5 × 0.45mm 
 Plate thickness   :  250µm 
 Source of radiation :  Deuterium lamp 
 Detection wavelength  : 288nm 
 Rf value                            :   Sofosbuvir 0.21 ± 0.02 
                                              Ledipasvir 0.43 ± 0.02 
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 The best solvent system hexane : ethyl aetate : methanol [4:5:2v/v/v] few 
drops of ammonia which resulted in good symmetric peak with Rf value sofosbuvir 
0.21 ± 0.02 and Ledipasvir 0.43 ± 0.02 was selected as optimized mobile phase to 
achieve adequate separation of ledipasvir and sofosbuvir peaks. At higher 
proportion of hexane composition, the drug was retained at the spot of application 
and the Rf value less than 0.1 which was not ideal for quantitative determination. 
The blank and the standard chromatogram are shown in figure 11-12. 
Figure 11: Chromatogram of Blank 
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Figure 12: Standard chromatogram of Ledipasvir and sofosbuvir         
(200ng/spot&880ng/spot) 
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VALIDATION: 
Linearity: 
            The high correlation coefficient obtained from linear regression analysis 
showed good linear relationship over the concentration range of ledipasvir  
100-700ng/spot and sofosbuvir 440-3080ng/spot that was shown in figure  
13 - 19and set of data were tabulated in table 13 &14. The correlation coefficient, 
slope, and intercept were found (table 12), which was obtained from calibration 
graph and is shown in figure 20. 
Table 12: Regression data 
Linear regression 
parameters Ledipasvir Sofosbuvir 
Slope 4.847 1.461 
Intercept 349.9 870.4 
Correlation coefficient 0.994 0.992 
Figure 13: Chromatogram of Ledipasvir (100ng/ spot) and 
Sofosbuvir(440ng/spot) 
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Figure 14: Chromatogram of Ledipasvir (200ng/ spot) and 
Sofosbuvir(880ng/spot) 
 
Figure 15: Chromatogram of Ledipasvir (300ng/ spot) and 
Sofosbuvir(1320ng/spot) 
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Figure 16: Chromatogram of Ledipasvir (400ng/ spot) and 
Sofosbuvir(1760ng/spot) 
 
Figure 17: Chromatogram of Ledipasvir (500ng/ spot) and 
Sofosbuvir(2200ng/spot) 
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Figure 18: Chromatogram of Ledipasvir (600ng/ spot) and Sofosbuvir 
(2640ng/spot) 
 
Figure 19: Chromatogram of Ledipasvir (700ng/ spot) and 
Sofosbuvir(3080ng/spot) 
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Table 14: Calibration data of Ledipasvir 
Concentration (ng/spot) Peak Area 
100 731 
200 1375 
300 1943 
400 2503 
500 3044 
600 3844 
700 4422 
 
Table 15: Calibration data of sofosbuvir 
Concentration (ng/spot ) Peak Area 
440 1373 
880 2244 
1320 3018 
1760 3721 
2200 4342 
2640 4841 
3080 5385 
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Figure 21: Calibration graph of Ledipasvir 
 
Figure 21: Calibration graph of Sofosbuvir 
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ACCURACY: 
         Recovery studies were done for determining accuracy parameter. It was done 
by mixing known quantity of standard drug with the analysed sample formulation 
and the contents were reanalysed by the proposed method. Recovery studies were 
carried out at 50,100, and 150% levels. The percentage recovery and its %RSD were 
calculated, shown in table 16a and 16b. 
Table 16a :Recovery study for ledipasvir 
Level % Recovery %RSD* 
50% 99.41% 0.25 
100% 98.25% 0.52 
150% 101.84% 1.24 
*RSD of six determination 
Table 16b :Recovery study for sofosbuvir 
Level % Recovery %RSD* 
50% 100.25% 0.45 
100% 101.85% 0.89 
150% 100.89% 0.21 
*RSD of six determination 
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PRECISION 
 The method precision was obtained by determining the assay by preparing 
six samples of selected concentration (200 & 400ng/spot) of Ledipasvir and (880 & 
1760ng/spot) of sofosbuvir. The % RSD calculated for method precision of inter-
day, intra-day (table 17,18 and repeatability (repeatability of sample measurement 
and sample application respectively) are shown in table 19,20. 
Table 17: Intra-day precision  
Concentration 
(ng/spot) 
 
Peak area %RSD* 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
Ledipasvir  
(200ng/band) 
& 
Sofosbuvir 
(880ng/band) 
1375 2243 
0.344 1.049 
1368 2251 
1377 2207 
Ledipasvir 
(400ng/band) 
& 
Sofosbuvir 
(1760ng/band) 
2503 3722 
0.426 0.215 
2517 3775 
2496 3706 
*RSD of three determination 
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Table 18:Inter-day precision  
Concentration 
(ng/spot) 
Peak area %RSD* 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
Ledipasvir 
(200ng/band) 
& 
Sofosbuvir 
(880ng/band) 
1365 2201 
0.476 0.391 
1358 2212 
1371 2195 
Ledipasvir 
(400ng/band) 
& 
Sofosbuvir 
(1760ng/band) 
2576 3710 
0.427 1.601 
2586 3728 
2564 3618 
*RSD of three determination 
Table 19: Repeatability of sample measurement 
Concentration 
(ng/spot) 
Peak area % RSD* 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
Ledipasvir 
(200ng/band) 
& 
Sofosbuvir 
(880ng/band) 
1389 2296 
0.615 1.517 
1370 2269 
1390 2258 
1385 2205 
1381 2218 
1394 2233 
*RSD six determination 
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                                     Table 20: Repeatability sample application 
Concentration 
(ng/spot) 
Peak area % RSD* 
Ledipasvir   Sofosbuvir Ledipasvir Sofosbuvir 
Ledipasvir 
(200ng/band) 
& 
Sofosbuvir 
(880ng/band) 
1368 2216 
0.393      0.334 
1371 2208 
1364 2227 
1378 2212 
1366 2223 
1375 2211 
*RSD six determination 
LOD and LOQ: 
 Limit of detection and limit of quantification that were calculated from the 
equation. The result  was shown in table 21a and 21b , that proved the sensitivity of 
the method. 
Table 21a: Results of LOD & LOQ of ledipasvir 
Correlation coefficient±SD* 0.9948   ±0.0004590 
Slope ± SD* 4.847   ±0.001049 
Intercept ± SD*                    349.9 ±0.1941 
LOD(ng / spot) 0.13 ng / spot 
LOQ(ng / spot) 0.40 ng / spot 
*RSD of six determinations. 
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Table 21b: Results of LOD & LOQ of Sofosbuvir 
Correlation coefficient ± SD* 0.9927   ±0.0003435 
Slope ± SD* 1.461   ±0.001581 
Intercept ± SD*                    870.4 ±0.1924 
LOD  (ng / spot) 0.4345 ng / spot 
LOQ  (ng / spot) 1.316 ng / spot 
*RSD of six determinations. 
Robustness: 
 The study was confirmed to be robust as the Rf value and peak area was not 
much affected by introducing slight changes in the experimental conditions, that 
was shown in table 22 . 
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Table 22: Robustness evaluation  
(200 Ledipasvir and 440 Sofosbuvir ng/spot) 
MOBILE PHASE COMPOSITION: 
FACTOR LEVEL 
PEAK AREA % RSD * 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
4:5:1(10ml) 
-0.1 1370 2241 1.02 0.84 
0 1375 2244 0.96 0.48 
+0.1 1360 2254 0.85 0.45 
MOBILE PHASE VOLUME: 
FACTOR LEVEL 
PEAK AREA % RSD * 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
10ml 
-0.1 1350 2247 0.78 1.44 
0 1380 2265 0.65 1.04 
+0.1 1375 2278 0.89 0.89 
CHAMBER SATURATION TIME: 
FACTOR LEVEL PEAK AREA % RSD* Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
20 minutes 
-5 1358 2304 0.36 0.69 
0 1369 2245 0.89 0.80 
+5 1398 2278 0.78 0.92 
SOLVENT MIGRATION DISTANCE : 
FACTOR LEVEL PEAK AREA % RSD* Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
80mm 
+5 1365 2245 0.25 0.12 
0 1368 2244 0.75 0.02 
-5 1369 2249 0.48 0.09 
* Mean of six observations 
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Specificity: 
 The peak purity index at the peak start, peak apex and peak end was 
determined and was found to be about 0.999661 and 0.999978(ledipasvir)and 
0.999458 and 0.999847 of sofosbuvir that was shown in table 23a and 23b. This 
proved high specificity of the method thereby developed. 
Table 23a:  Specificity of ledipasvir 
Peak purity Peak purity index 
r(s* , m*) 0.999661 
r(m* , e*) 0.999978 
s*peak start, m*apex and e*peak end 
Table 23b:  Specificity of Sofosbuvir 
Peak purity Peak purity index 
r(s* , m*) 0.999458 
r(m* , e*) 0.999847 
s*peak start, m*apex and e*peak end 
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STABILITY STUDIES  
Stability of chromatographic plate 
  When the developed chromatographic plate was exposed to atmosphere, the 
analytes are likely to decomposed. Hence it was necessary to conduct stability 
studies of the plate.  
 Stability of the analyte on the plate was studied at different time intervals 
and peak areas were compared with peak area of freshly scanned plate. The 
developed plate was found to be stable for upto 24hrs, table 24a and 24b. 
Table 24a: Ledipasvir 
Time (hr) Concentration(ng/spot) Peak area 
 
0 
200 
400 
2244 
               3721 
 
6 
200 
400 
2201 
3608 
 
24 
200 
400 
2017 
3415 
 
Table 24b: sofosbuvir 
Time (hr) Concentration(ng/spot) Peak area 
0 
880 
1760 
1375 
2503 
6 
880 
1760 
1310 
2445 
24 
880 
1760 
1125 
2278 
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ANALYSIS OF TABLET FORMULATION 
 The % label claim was calculated and the estimated amount was close to the 
labelled value that was shown in figure 22 and table 25. 
Figure 22: Chromatogram of Ledipasvir and Sofosbuvir 
 
Table 25: Analysis of formulation 
Drug Name 
(cimivir-L) 
Amount (mg/tab) % Label 
claim %RSD* Labelled Estimated 
Ledipasvir 90 91.45 101.61 0.25 
Sofosbuvir 400 399.05 99.76 0.38 
*RSD of six observations 
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FORCED DEGRADATION STUDIES: LEDIPASVIR 
Acid hydrolysis: 
 Ledipasvir was subjected to acid hydrolysis, an additional peak was 
observed along with standard, Rf value of 0.34, which is shown in figure 23a &23b. 
               Figure 23a: Chromatogram of acid hydrolysis of Ledipasvir 
 
               Figure 23b: Spectrum of Ledipasvir and Degradant 
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Alkaline hydrolysis: 
 The drug was subjected to alkaline hydrolysis additional peaks were 
observed at Rf value 0.34,  which was shown in figure 24a &24b. 
Figure 24a: Chromatogram of base hydrolysis of Ledipasvir 
 
               Figure 24b: Spectrum of ledipasvir and degradant 
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Neutral hydrolysis: 
 The drug was subjected to neutral  hydrolysis no additional peaks were 
observed, which was shown in figure 25a & 25b. 
                 Figure 25a: Chromatogram of neutral hydrolysis of Ledipasvir 
 
               Figure 25b: Spectrum of ledipasvir 
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Oxidative degradation: 
 The drug was subjected to oxidation additional peaks were observed at Rf 
value 0.34,  which was shown in figure 26a & 26b. 
Figure 26a: Chromatogram of oxidative degradation of Ledipasvir 
 
               Figure 26b: Spectrum of ledipasvir and degradant 
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Photolytic degradation: 
 The drug was subjected to photolytic degradation  additional peaks were 
observed at Rf value 0.34,  which was shown in figure 27a & 27b. 
Figure 27a: Chromatogram of photolytic degradation of ledipasvir 
 
               Figure 27b: Spectrum of ledipasvir and degradant 
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Thermal degradation 
 The drug was subjected to thermal degradation additional peaks were 
observed at Rf value 0.34,  which was shown in figure 28a & 28b. 
Figure 28a: Chromatogram of thermal degradation of Ledipasvir 
 
               Figure 28b: Spectrum of ledipasvir and degradant 
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 Summary of forced degradation was shown in the table 26. 
Table 26 Summary of forced degradation studies for Ledipasvir: 
Type of 
stress Stress condition 
Rf value  
Drug Degraded Product 
Acid 
hydrolysis 
Drug refluxed 
with 0.1M HCl 
for about 5 hours 
0.43±0.02 0.34 ± 0.02 
Basic 
hydrolysis 
Drug refluxed 
with 0.1M NaoH 
for about 5 hours 
0.43±0.02 0.34 ± 0.02 
Neutral 
hydrolysis 
Drug treated 
with water and 
refluxed for 
about 5 hours 
0.43±0.02 No additional peaks 
Oxidative 
degradation 
Drug treated 
with 
6 % hydrogen 
peroxide at 
normal room 
temperature 
0.43±0.02 0.34± 0.02 
Photo 
degradation 
Drug exposed to 
Sunlight for 5 
hours 
0.43±0.02 0.34± 0.02 
 
Thermal 
degradation 
Drug introduced 
in Hot air oven 
for 5 hours 
 
0.43±0.2 
0.34± 0.02 
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FORCED DEGRADATION STUDIES: SOFOSBUVIR 
Acid hydrolysis: 
 Sofosbuvir was subjected to acid hydrolysis, no additional peak was 
observed along with standard,  that is shown in figure 29a & 29b. 
Figure 29a: Chromatogram of acid hydrolysis of Sofosbuvir 
 
               Figure 29b: Spectrum of Sofosbuvir  
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Alkaline hydrolysis: 
 The drug was subjected to alkaline hydrolysis three additional peaks were 
observed at Rf  0.12, 0.28 and 0.33 value which was shown in figure 30a & 30b. 
Figure 30a: Chromatogram of base hydrolysis of Sofosbuvir 
 
               Figure 30b: Spectrum of Sofosbuvir and degradant 
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Neutral hydrolysis: 
 The drug was subjected to neutral  hydrolysis no additional peaks were 
observed,  which was shown in figure 31a & 31b 
                 Figure 31a: Chromatogram of neutral hydrolysis of Sofosbuvir 
 
               Figure 31b: Spectrum of Sofosbuvir 
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Oxidative degradation: 
 The drug was subjected to oxidation no additional peaks were observed at 
Rf value 0.04,  which was shown in figure 32a & 32b. 
Figure 32a: Chromatogram of oxidative degradation of Sofosbuvir 
 
               Figure 32b: Spectrum of Sofosbuvir and 
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Photolytic degradation: 
 The drug was subjected to photolytic degradation no additional peaks were 
observed,  which was shown in figure 33a & 33b. 
Figure 33a: Chromatogram of photolytic degradation of Sofosbuvir 
 
               Figure 33b: Spectrum of Sofosbuvir 
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Thermal degradation 
 The drug was subjected to thermal degradation no additional peaks were 
observed,  which was shown in figure 34a & 34b. 
Figure 37: Chromatogram of thermal degradation of Sofosbuvir 
 
               Figure 34b: Spectrum of Sofosbuvir and degradant 
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 Summary of forced degradation was shown in the table 27. 
Table 27 Summary of forced degradation studies for Sofosbuvir: 
Type of stress Stress condition 
Rf value  
Drug Degraded Product 
Acid 
hydrolysis 
Drug refluxed 
with 0.1M HCl 
for about 5 hours 
0.21±0.02 No additional peaks 
Basic 
hydrolysis 
Drug refluxed 
with 0.1m NaoH 
for about 5 hours 
0.21±0.02 
0.12 ± 0.02 
0.28 ± 0.02 
0.33± 0.02 
Neutral 
hydrolysis 
Drug treated with 
water and 
refluxed for about 
5 hours 
0.21±0.02 No additional peaks 
Oxidative 
degradation 
Drug treated with 
6% hydrogen 
peroxide at 
normal room 
temperature 
0.21±0.02 No additional peaks 
Photo 
degradation 
Drug exposed to 
Sunlight for 5 
hours 
0.21±0.02 No additional peaks 
Thermal 
degradation 
Drug introduced 
in Hot air oven 
for 5 hours 
0.21±0.2 No additional peaks 
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FORCED DEGRADATION STUDIES: LEDIPASVIR AND SOFOSBUVIR 
Acid hydrolysis: 
  Ledipasvir and sofosbuvir were subjected to acid hydrolysis, an additional 
peak was observed along with standards, Rf value of 0.34 that is shown in  
figure 35a & 35b. 
Figure 35a: Chromatogram of acid hydrolysis of ledipasvir and sofosbuvir 
 
               Figure 35b: Spectrum of Ledipasvir, Sofosbuvir and degradants 
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Alkaline hydrolysis: 
 The drug was subjected to alkaline hydrolysis two additional peaks were 
observed at Rf  0.12, 0.28 and 0.34value which was shown in figure 36a & 36b. 
               Figure 36a: Chromatogram of alkaline hydrolysis of ledipasvir and 
sofosbuvir 
 
               Figure 36b: Spectrum of Ledipasvir, Sofosbuvir and degradants 
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Neutral hydrolysis: 
 Ledipasvir and sofosbuvir were subjected to neutral hydrolysis no additional 
peaks were observed, which was shown in figure 37a & 37b. 
               Figure 37a: Chromatogram of neutral hydrolysis of ledipasvir and 
sofosbuvir 
 
               Figure 37b: Spectrum of Ledipasvir and Sofosbuvir 
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Oxidative degradation: 
 Ledipasvir and sofosbuvir were was subjected to oxidation additional peaks 
were observed at Rf value 0.34 ,  which was shown in figure 38a & 38b. 
               Figure 38a: Chromatogram of Oxidative degradation of ledipasvir 
and sofosbuvir 
 
               Figure 38b: Spectrum of Ledipasvir, Sofosbuvir and degradants 
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Photolytic degradation: 
 Ledipasvir and sofosbuvir were was subjected to photolytic degradation 
additional peaks were observed at Rf value 0.34,  which was shown in figure 39a 
&39b. 
               Figure 39a: Chromatogram of photolytic degradation of ledipasvir 
and sofosbuvir 
 
               Figure 39b: Spectrum of Ledipasvir, Sofosbuvir and degradants 
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Thermal degradation 
            The drug was subjected to thermal degradation additional peaks were 
observed at Rf value 0.34,  which was shown in figure 40a & 40b. 
Figure 40a: Chromatogram of thermal degradation of ledipasvir and 
sofosbuvir 
 
               Figure 340b: Spectrum of Ledipasvir, Sofosbuvir and degradant 
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Table 28: Summary of forced degradation studies for Ledipasvir and 
Sofosbuvir: 
Type of stress Stress 
condition 
Rf value  
Ledipasvir Sofosbuvir Ledipasvir Degradant 
Sofosbuvir 
Degradant 
Acid 
hydrolysis 
Drugs 
refluxed 
with 0.1M 
HCl for 
about 5 
hours 
0.43±0.02 0.21 ± 0.02 0.34 ± 0.02 
No 
additional 
peaks 
Basic 
hydrolysis 
Drugs 
refluxed 
with 0.1m 
NaoH for 
about 5 
hours 
0.43±0.02 0.21 ± 0.02 0.34 ± 0.02 0.12 ± 0.02 0.28 ± 0.02 
Neutral 
hydrolysis 
Drugs 
treated with 
water and 
refluxed for 
about 5 
hours 
0.43±0.02 0.21± 0.02 
No 
additional 
peaks 
No 
additional 
peaks 
Oxidative 
degradation 
Drugs 
treated with 
6% 
hydrogen 
peroxide at 
normal 
room 
temperature 
0.43±0.02 0.21± 0.02 0.34± 0.02 
No 
additional 
peaks 
Photo 
degradation 
Drugs 
exposed to 
Sunlight for 
5 hours 
0.43±0.02 0.21± 0.02 0.34± 0.02 
No 
additional 
peaks 
Thermal 
degradation 
Drugs 
introduced 
in Hot air 
oven for 5 
hours 
0.43±0.2 0.21± 0.02 0.34± 0.02 
No 
additional 
peaks 
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DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE 
SIMULTANEOUS DETERMINATION OF LEDIPASVIR AND 
SOFOSBUVIR IN BULK AND FORMULATION 
 
 The Ledipasvir and Sofosbuvir is a polar in nature hence RP-HPLC method 
and C18 column was used for the HPLC method development and stability 
indicating for the ledipasvirand sofosbuvir. 
 
Selection of wavelength: 
 Good analytical separation can be obtained only by careful selection of 
wavelength for the detection (Fig. 41-43). The smooth obtained from which 254nm 
was select for the both drug was recorded on HPLC system. 
 
Fig. 41 Spectrum of Ledipasvir 
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Fig. 42 Spectrum of Sofosbuvir 
 
 
Fig. 43 Overlay Spectrum of Ledipasvar and Sofosbuvir 
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SELECTION OF THE MOBILE PHASE 
           Based on the solubility and polarity, different mobile phases were tried and 
the chromatograms were recorded and results are displayed in table:29 
Table 29: Selection of Mobile Phase 
Mobile 
phase 
Ratio 
(%) Chromatograms Observation 
 
 
ACN 
 
 
100 
 
 
 
 
Both drugs not 
separate 
Water : 
Methanol 
 
80:20 
 
 
 
Broad peak 
and 
Less 
resolution 
 
Water : 
ACN 
 
 
80:20 
 
 
 
Good 
resolution 
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SELECTION OF BUFFER: 
           In the mobile phase system consisting of 1% orthophosphoric acid: 
acetonitrile, different buffers like phosphate and acetate. The chromatogram were 
recorded and results are given in table 30. 
Table30 : Selection of Buffer 
S. 
no 
Buffer Chromatograms Observation 
 
1. 
 
 
 
Photassium 
di hydrogen 
Phosphate: 
ACN 
 
Split peak 
2. 
 
Ammonium 
acetate: 
ACN 
 
Peak tailing 
3. 
1% ortho 
phosphoric 
acid: ACN 
 
Good peak 
shape & 
good 
resolution 
 
 
                                                            Result and Discussion-HPLC 
 
 
Department of Pharmaceutical Analysis   112 
 
Selection of flow rate: 
 Keeping the ratio of mobile phase constant (30;70 v/v), the chromatogram 
were recorded with different pH like 3.4, 6.0, 6.4 and 6.9 were tried. For pH 6.4, 
good resolution and symmetrical peak was obtained and hence selected for further 
studies table 31. 
Table 31:Selection of Flow Rate 
S. 
no 
Flow rate 
(ml/min) Chromatogram Observation 
 
1 
 
0.5ml/min 
 
 
Ledipasvir 
Rt> 10min 
 
2 
 
0.8ml/min 
 
 
Symmetric 
peak & Good 
resolution 
 
3 
 
0.9ml/min 
 
 
Medium 
resolution 
FIXED CHROMATOGRAPHIC CONDITIONS 
Chromatographic method     :  RP-HPLC 
Column (stationary phase)   :     Hibar, C18 column (250mmx 4.0mm, 5µm) 
Mobile phase                        : 1% orthophosphoric acid (pH6.4): Acetonitrile       
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Ratio of mobile phase        :     30:70 v/v 
Detection of wavelength     :     254nm  
Flow rate      :     0.8ml/min 
Retention time                     :     Sofosbuvir 3.7 ± 0.02 
                                                   Ledipasvir 7.1 ± 0.02 
Temperature  : Room temperature 
Linearity and range: 
A calibration graph was plotted with measured peak areas against 
concentration. From the graph it was found that ledipasvir and sofosbuvir shows 
good linearity in the concentration range 1-10µg/ml and 1-10µg/ml. The peak area 
of these solutions was measured at 254nm. The slope, intercept, and correlation 
coefficient values were calculated respectively (table 32). The linear graph and 
standard chromatogram obtained are shown in fig 44 to 56. The linearity table is 
shown in table 33 and 34. 
Table 32: Regression data 
Linear regression Ledipasvir Sofosbuvir 
Slope 5976.13 0.13807.7 
Intercept 14699.1 24637.8 
Correlation 
coefficient 0.9987 0.9995 
                                   
Figure 44: Chromatogram of Blank 
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Fig 45: Chromatogram of ledipasvir (1µg/ml)and sofosbuvir (1µg/ml) 
 
Fig 46: Chromatogram of ledipasvir (2µg/ml)and sofosbuvir (2µg/ml) 
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Fig 47: Chromatogram of ledipasvir (3µg/ml)and sofosbuvir (3µg/ml) 
 
Fig 48: Chromatogram of ledipasvir (4µg/ml)and sofosbuvir (4µg/ml) 
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Fig 49: Chromatogram of ledipasvir (5µg/ml)and sofosbuvir (5µg/ml) 
 
Fig 50: Chromatogram of ledipasvir (6µg/ml)and sofosbuvir (6µg/ml) 
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Fig 51: Chromatogram of ledipasvir (7µg/ml)and sofosbuvir (7µg/ml) 
 
Fig 52: Chromatogram of ledipasvir (8µg/ml)and sofosbuvir (8µg/ml) 
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Fig 53: Chromatogram of ledipasvir (9µg/ml)and sofosbuvir (9µg/ml) 
 
Fig 54: Chromatogram of ledipasvir (10µg/ml)and sofosbuvir (10µg/ml) 
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Table 33: Calibration data for Ledipasvir 
Concentration(µg/ml) Peak area 
1 17517 
2 36796 
3 48253 
4 65251 
5 82453 
6 95549 
7 110564 
8 125468 
9 135894 
10 150468 
 
Table 33: Calibration data for Sofosbuvir 
Concentration(µg/ml) Peak area 
1 12267 
2 36018 
3 57611 
4 84734 
5 110043 
6 132226 
7 162341 
8 181393 
9 204639 
10 235708 
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Fig 55: Calibration graph of Ledipasvir (1-10µg/ml) 
 
Fig 56: Calibration graph of Sofosbuvir (1-10µg/ml) 
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Recovery study: 
          Recovery studies were carried out at 50,100, and 150% levels. The 
percentage recovery and its %RSD were calculated, shown in table 33a & 33b. 
Table 33a :Recovery study for Ledipasvir 
Level % Recovery %RSD* 
50% 98.34% 0.05 
100% 98.01% 0.84 
150% 99.27% 0.94 
*RSD of six determination 
Table 33b: Recovery study for Sofosbuvir 
Level % Recovery %RSD* 
50% 99.73% 0.54 
100% 100.36% 0.25 
150% 101.48% 0.14 
*RSD of six determination 
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Precision:  
Intra-day and inter-day precision: 
Intra-day and inter-day precision was determined by injecting standard 
solutions in between linearity range (4 and 8µg/ml for ledipasvir and 4and 8µg/ml 
for sofosbuvir) were injected for three times and % RSD was calculated (table 34, 
and 35). 
Table 34: Intra-day precision 
Concentration 
(ng/spot) 
Peak area %RSD* 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
Ledipasvir(4µg/ml) 
& 
Sofosbuvir (4 µg/ml) 
65221 84645 
0.0123 0.0270 65531 84660 
65537 84690 
Ledipasvir(8 µg/ml) 
& 
Sofosbuvir (8 µg/ml) 
125378 181499 
0.0300 0.0185 125319 181491 
125308 181437 
*RSD of three determinations 
Table 35: Inter-day precision 
Concentration 
(ng/spot) 
Peak area %RSD* 
Ledipasvir Sofosbuvir Ledipasvir Sofosbuvir 
Ledipasvir(4µg/ml) 
& 
Sofosbuvir (4 µg/ml) 
65310 84650 
0.0177 0.0343 65319 84666 
65333 84609 
Ledipasvir(8 µg/ml) 
& 
Sofosbuvir (8 µg/ml) 
124219 181409 
0.0065 0.0128 124225 181410 
124009 181450 
*RSD of three determinations 
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Repeatability: 
   Repeatability of injection was determined by injecting standard solutions 
(4µg/ml) of ledipasvir and (4µg/ml) of sofosbuvir for six times, noted peak areas 
and % RSD was calculated table 36a & 36b. 
                                  Table 36a: Repeatability injection of Ledipasvir 
Concentration (µg/ml) Repeatability % RSD* 
4 
65251 
0.0215 
65242 
65255 
65235 
65260 
65275 
*RSD of six determinations 
Table 36b: Repeatability injection of Sofosbuvir 
Concentration (µg/ml) Repeatability % RSD* 
 
4 
 
84734 
0.0102 
84712 
84722 
84730 
84725 
84735 
*RSD of six determinations 
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Limit of detection and limit of quantification (LOD and LOQ): 
              Limit of detection and limit of quantification that were calculated from the 
equation. The result  was shown in table 37a & 37b , that proved the sensitivity of 
the method. 
Table 37a: Results of LOD & LOQ of Ledipasvir 
Correlation coefficient     ±SD* 0.9987   ±0.0001342 
Slope                                 ±SD* 3.123  ± 2.608 
Intercept                            ± SD* 1112.65   ±2.436 
LOD  (ng / spot) 0.008µg / ml 
LOQ  (ng / spot) 0.27µg / ml 
*RSD of six determinations. 
Table 37b: Results of LOD & LOQ of Sofosbuvir 
Correlation coefficient     ±SD* 0.9995  ±0.4080 
Slope                                 ±SD* 3.123   ±2.611 
Intercept                            ± SD* 1112.65   ±2.822 
LOD  (ng / spot) 0.0006µg /ml 
LOQ  (ng / spot) 0.0020 µg / ml 
*RSD of six determinations. 
Specificity:  
  There were no additional peaks observed while injecting solvents or mobile 
phase alone. The peak purity index of standard ledipasvir 0.9998 and sofosbuvir 
0.9995. 
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Robustness: 
In order to demonstrate the robustness of the method, the following 
optimized conditions were slightly changed.  
      ± 0.1ml flow rate  
     ± 2% organic solvent 
      ± 0.5 PH 
     The responses for these changed chromatographic parameters were almost 
same for the fixed chromatographic parameters and hence the developed method 
was said to be robustness 
Stability of solution: 
    The solution under room temperature was stable for 24 hours. (Table 38) 
Table 38: Stability of solution 
Hours 
Ledipasvir Sofosbuvir 
Concentration 
(µg/ml) Peak area 
Concentration 
(µg/ml) Peak area 
0 hrs 
5 
82453 
5 
110043 
6 hrs 82412 110012 
24 hrs 82219 109702 
System suitability studies: 
  The system suitability parameters like peak area, tailing factor, theoretical 
plate count, resolution, and retention time were calculated from the standard 
chromatogram (table 39). 
Table 39: System suitability studies 
Drug Theoretical plate(N) 
Retention 
time(min) 
Tailing 
factor 
(10%) 
Resolution 
Ledipasvir 2703 3.7 1.062 - 
Sofosbuvir 1762 7.1 0.994 6.90 
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ANALYSIS OF TABLET FORMULATION 
  The % label claim was calculated and the estimated amount was close to 
the labelled value that was shown in figure 57 and table 40. 
Figure 27: Chromatogram of Ledipasvir and Sofosbuvir 
 
Table 40: Analysis of formulation 
 
Drug Name 
(cimivir-L) 
Amount (mg/tab) 
% Label 
claim %RSD* Labelled Estimated 
Ledipasvir 90 89.34 99.30 0.41 
Sofosbuvir 400 398.17 99.54 0.67 
*RSD of six observations 
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FORCED DEGRADATION STUDIES: LEDIPASVIR 
Acid hydrolysis: 
 Ledipasvir was subjected to acid hydrolysis, no additional peak was 
observed along with standard, which is shown in figure 58a & 58b. 
Figure 58a: Chromatogram of acid hydrolysis of Ledipasvir 
 
Figure 58b: Spectrum of Ledipasvir 
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Alkaline hydrolysis: 
 The drug was subjected to alkaline hydrolysis additional peaks were 
observed,  which was shown in figure 59a & 59b. 
Figure 59a: Chromatogram of base hydrolysis of Ledipasvir 
 
Figure 59b: Spectrum of Ledipasvir 
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Neutral hydrolysis: 
 The drug was subjected to neutral  hydrolysis no additional peaks 
were observed, which was shown in figure 60a & 60b. 
 
Figure 60a: Chromatogram of neutral hydrolysis of Ledipasvir 
 
Figure 60b: Spectrum of Ledipasvir 
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Oxidative degradation: 
 The drug was subjected to oxidation no additional peaks were observed,  
which was shown in figure 61a & 61b. 
Figure 61a: Chromatogram of oxidative degradation of Ledipasvir 
 
Figure 61b: Spectrum of Ledipasvir 
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Photolytic degradation: 
 The drug was subjected to photolytic degradation no additional 
peaks were observed,  which was shown in figure 62a &62b. 
Figure 62a: Chromatogram of photolytic degradation of Ledipasvir 
 
Figure 62b: Spectrum of Ledipasvir  
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Thermal degradation 
 The drug was subjected to thermal degradation additional peaks were 
observed at Rf value 0.34,  which was shown in figure 63a & 63b. 
Figure 63a: Chromatogram of thermal degradation of Ledipasvir 
 
Figure 63b: Spectrum of Ledipasvir 
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Summary of forced degradation was shown in the table 41. 
Table 41 Summary of forced degradation studies for Ledipasvir: 
Type of 
stress Stress condition 
Retention time(min) 
Drug Degraded Product 
Acid 
hydrolysis 
Drug refluxed 
with 0.1M HCl 
for about 5 hours 
7.1 No additional peak 
Basic 
hydrolysis 
Drug refluxed 
with 0.1M NaoH 
for about 5 hours 
 
7.1 No additional peak 
Neutral 
hydrolysis 
Drug treated 
with water and 
refluxed for 
about 5 hours 
 
7.1 No additional peak 
Oxidative 
degradation 
Drug treated 
with 
6 % hydrogen 
peroxide at 
normal room 
temperature 
 
7.1 
No additional peak 
Photo 
degradation 
Drug exposed to 
Sunlight for 5 
hours 
 
7.1 No additional peak 
 
Thermal 
degradation 
 
Drug introduced 
in Hot air oven 
for 5 hours 
 
7.1 No additional peak 
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FORCED DEGRADATION STUDIES: SOFOSBUVIR 
Acid hydrolysis: 
 Sofosbuvir was subjected to acid hydrolysis, no additional peak was 
observed , that is shown in figure 64a & 64b. 
               Figure 64a: Chromatogram of acid hydrolysis of Sofosbuvir 
 
Figure 64b: Spectrum of Sofosbuvir 
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Alkaline hydrolysis: 
 The drug was subjected to alkaline hydrolysis three additional peaks were 
observed at Rt  2.8 and 4.1 value which was shown in figure 65a,65b,66c & 66d. 
Figure 65a: Chromatogram of base hydrolysis of Sofosbuvir 
 
Figure 65b: Spectrum of Sofosbuvir 
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Figure 65c: Spectrum of Sofosbuvir degradant 
 
Figure 65d: Spectrum of Sofosbuvir degradant 
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Neutral hydrolysis: 
 The drug was subjected to neutral  hydrolysis no additional peaks 
were observed,  which was shown in figure 66a &66b. 
Figure 66a: Chromatogram of neutral hydrolysis of Sofosbuvir 
 
Figure 66b: Spectrum of Sofosbuvir 
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Oxidative degradation: 
 The drug was subjected to oxidation no additional peaks were 
observed,  which was shown in figure 67a &67b. 
Figure 67a: Chromatogram of oxidative degradation of Sofosbuvir 
 
Figure 67b: Spectrum of Sofosbuvir 
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Photolytic degradation: 
 The drug was subjected to photolytic degradation no additional peaks were 
observed,  which was shown in figure 68a. 
Figure 36: Chromatogram of photolytic degradation of Sofosbuvir 
 
Figure 68b: Spectrum of Sofosbuvir 
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Thermal degradation 
 The drug was subjected to thermal degradation no additional peaks were 
observed,  which was shown in figure 69a & 69b. 
 
Figure 69a: Chromatogram of thermal degradation of Sofosbuvir 
 
Figure 69b: Spectrum of Sofosbuvir 
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Summary of forced degradation was shown in the table 42. 
Table 42 Summary of forced degradation studies for Sofosbuvir: 
Type of stress Stress condition 
Retention time(min) 
Drug Degraded Product 
Acid 
hydrolysis 
Drug refluxed 
with 0.1M HCl 
for about 5 hours 
3.7 No additional peak 
Basic 
hydrolysis 
Drug refluxed 
with 0.1m NaoH 
for about 5 hours 
 
3.7 
2.8±0.02 
4.1±0.02 
Neutral 
hydrolysis 
Drug treated with 
water and 
refluxed for about 
5 hours 
 
3.7 
 
No additional peak 
Oxidative 
degradation 
Drug treated with 
6% hydrogen 
peroxide at 
normal room 
temperature 
 
3.7 
 
No additional peak 
Photo 
degradation 
Drug exposed to 
Sunlight for 5 
hours 
 
3.7 
 
No additional peak 
Thermal 
degradation 
Drug introduced 
in Hot air oven 
for 5 hours 
 
3.7 
 
No additional peak 
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FORCED DEGRADATION STUDIES: LEDIPASVIR AND SOFOSBUVIR 
Acid hydrolysis: 
 Ledipasvir and sofosbuvir were subjected to acid hydrolysis, no additional 
peak was observed, that is shown in figure 70a & 70b. 
Figure 70a: Chromatogram of acid hydrolysis of Ledipasvir and Sofosbuvir 
 
Figure 70b: Spectrum of Ledipasvir and Sofosbuvir 
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Alkaline hydrolysis: 
 The drug was subjected to alkaline hydrolysis two additional peaks were 
observed at Rt  3.1 and 4.2 value which was shown in figure 71a,71b,71c & 71d. 
Figure 71a: Chromatogram of alkaline hydrolysis of Ledipasvir and 
Sofosbuvir 
 
Figure 71b: Spectrum of Ledipasvir and Sofosbuvir 
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Figure 71c: Spectrum of Sofosbuvir degradants 
 
Figure 71d: Spectrum of Sofosbuvir degradants 
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Neutral hydrolysis: 
 Ledipasvir and sofosbuvir were subjected to neutral hydrolysis no additional 
peaks were observed, which was shown in figure 72a & 72b. 
Figure 72a: Chromatogram of neutral hydrolysis of ledipasvir and sofosbuvir 
 
Figure 72b: Spectrum of Ledipasvir and Sofosbuvir 
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Oxidative degradation: 
 Ledipasvir and sofosbuvir were was subjected to oxidation no additional 
peaks were observed ,  which was shown in figure 73a &73b. 
Figure 73a: Chromatogram of Oxidative degradation of Ledipasvir and 
Sofosbuvir 
 
Figure 73b: Spectrum of Ledipasvir and Sofosbuvir 
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Photolytic degradation: 
 Ledipasvir and sofosbuvir were was subjected to photolytic degradation no 
additional peaks were observed at,  which was shown in figure 74a & 74b. 
Figure 74a: Chromatogram of neutral hydrolysis of Ledipasvir and 
Sofosbuvir 
 
Figure 74b: Spectrum of Ledipasvir and Sofosbuvir 
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Thermal degradation 
 The drug was subjected to thermal degradation no additional peaks 
were observed,  which was shown in figure 75a & 75b. 
Figure 75a : Chromatogram of thermal degradation of ledipasvir and 
sofosbuvir 
 
Figure 75b: Spectrum of Ledipasvir and Sofosbuvir 
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Table 43 Summary of forced degradation studies for Ledipasvir and 
Sofosbuvir: 
Type of 
stress 
Stress 
condition 
Retention time(min) 
Ledipasvir Sofosbuvir Ledipasvir Degradant 
Sofosbuvir 
Degradant 
Acid 
hydrolysis 
Drugs 
refluxed 
with 0.1M 
HCl for 
about 5 
hours 
7.1 3.7 
No 
additional 
peak 
 
No 
additional          
peak 
Basic 
hydrolysis 
Drugs 
refluxed 
with 0.1m 
NaoH for 
about 5 
hours 
 
7.1 
 
3.7 No 
additional 
peak 
 
2.8±0.02 
4.1±0.02 
Neutral 
hydrolysis 
Drugs 
treated with 
water and 
refluxed for 
about 5 
hours 
 
7.1 
 
3.7 No 
additional 
peak 
 
No 
additional 
peak 
Oxidative 
degradation 
Drugs 
treated with 
6% 
hydrogen 
peroxide at 
normal 
room 
temperature 
 
7.1 
 
3.7 
No 
additional 
peak 
 
No 
additional 
peak 
Photo 
degradation 
Drugs 
exposed to 
Sunlight for 
5 hours 
 
7.1 
 
3.7 
No 
additional 
peak 
No 
additional 
peak 
 
Thermal 
degradation 
Drugs 
introduced 
in Hot air 
oven for 5 
hours 
 
7.1 
 
3.7 
No 
additional 
peak 
No 
additional 
peak 
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SUMMARY AND CONCLUSION 
 Each year 3,99,000 people were died for hepatitis C. Ledipasvir and 
Sofosbuvir are the two anti-viral lifesaving drugs commonly used in combination 
for treating hepatitis C.  
 The present study deals with development and validation of a two simple, 
economical UV Spectroscopic methods, and two sensitive, reliable stability 
indicating HPTLC and HPLC methods for simultaneous estimation of Ledipasvir 
and Sofosbuvir in pure and fixed dose combination. 
 The UV Spectroscopic methods involved by solving (i)simultaneous 
equation (ii)second order derivative methods. The two selected wavelengths were 
333 nm  (Ȝmax of LEDI) and 261 nm (Ȝmax of SOF) for both the methods.  
Linearity was observed in the concentration range of 10 – 40 mcg/ml  for  LEDI  
and  10 ‐ 70  mcg/ml  for  SOF, respectively. 
 The stability indicating HPTLC method involved using TLC plates 
precoated with Silica gel G60F254 and the mobile phase comprising n-hexane: ethyl 
acetate: methanol in the ratio of 4: 5: 1 v/v/v. Ledipasvir and Sofosbuvir were well 
resolved with Rf 0.43 ± 0.02 and 0.21 ± 0.02, respectively. Wavelength selected for 
the quantification was 288 nm. Inherent stability of these drugs was studied by 
exposing both drugs to various stress conditions as per ICH guidelines viz. thermal, 
oxidative, photolysis and hydrolytic conditions under different pH values. 
Ledipasvir showed an additional peak (Rf = 0.34) in all stress condition except for 
neutral hydrolysis. Whereas Sofosbuvir showed three additional peaks at Rf = 0.12, 
0.28 and 0.33, respectively. The specificity of the method was confirmed by peak 
purity profile of the resolved peaks which were found to be close to 1. 
 In the stability-indicating reverse phase high performance liquid 
chromatography method, the wavelength selected for quantitation was 254 nm. 
(The method has been validated for linearity, accuracy, precision, robustness, limit 
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of detection and limit of quantification. Linearity was observed in the concentration 
range of 1-10 ȝg/ml for both the drugs). In this method, the separation was achieved 
by Hibar C18 (250×4.6mm) 5µm column using 1% O-Phosphoric acid  
(pH 6.4):Acetonitrile (30:70 v/v) as mobile phase with flow rate 0.8 ml/min. The 
retention time of ledipasvir and sofosbuvir were found to be 7.1min and 3.7 min, 
respectively. During force degradation, drug product was exposed to hydrolysis 
(acid and base hydrolysis), oxidation, thermal degradation and photo degradation. 
Both the drugs were not degraded under thermal, oxidative, photolytic, acid and 
neutral hydrolytic conditions, but Sofosbuvir showed degradation under alkaine 
hydrolytic condition with a retention time 2.8 min and 4.1 min, respectively. The 
degraded products of Ledipasvir and Sofosbuvir were well resolved from the 
individual bulk drug response. The specificity of the method was confirmed by peak 
purity profile of the resolved peaks.  
 All the developed methods were validated according to ICH guidelines and 
were found to be simple, specific, sensitive, accurate, precise and economic, hence 
the proposed methods could be used for simultaneous estimation of Ledipasvir and 
Sofosbuvir in tablet dosage form. Among these methods UV spectroscopic methods 
are simple, reliable and less time consuming which could be an alternative for 
chromatographic analysis. 
                The summery of all the proposed methods are shown in table 44. 
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Table 44: Summery of the proposed methods 
 
 
Parameters 
 
UV-Spectroscopy methods HPTLC HPLC Simultaneous equation method Second order derivative 
LEDI SOFOS LEDI SOFO LEDI SOFO LEDI SOFO 
Working 
wavelength 
(nm) 
333 261 333 261 288 288 254 254 
Linearity 
range 
10-40 
µg/ml 10-70 µg/ml 
10-40 
µg/ml 10-70 µg/ml 100-700 ng/spot 440-3080 ng/spot 1-10 µg/ml 1-10 µg/ml 
Correlation 
co-efficent(r2) 0.9987 0.9972 0.9978 0.9982 0.994 0.992 0.9987 0.9995 
SD slope* 0.0211±0.00016 0.0350±0.0001 0.3571±0.0004 0.475±0.0008 4.847   ±0.0010 1.461   ±0.001 3.123  ± 2.608 3.123   ±2.611 
SD intercept* 0.02528±0.12 0.0172±0.0001 0.7857±0.14 0.0015±0.52 349.9 ±0.1941 870.4 ±0.192 1112.6 ±2.436 870.4 ±0.192 
Data point 6 6 6 6 6 6 6 6 
Molar 
absorptivity 
(L mol1 cm1) 
2640762 919303 - - - - - - 
LOD* 0.2424µg/ml 0.24246 µg/ml 0.0044µg/ml 0.004454µg/ml 0.13ng/spot 0.4345ng/spot 0.008 µg/ml 0.0006 µg/ml 
LOQ* 0.7347µg/ml 0.7347µg/ml 0.0134µg/ml 0.0134µg/ml 0.40ng/spot 1.316ng/spot 0.27 µg/ml 0.0020 µg/ml 
Assay % 99.12 99.60 102.24 99.74 101.61 99.76 99.30 99.54 
Recovery 
(i)   50% 
(ii)  100% 
(iii) 150% 
 
99.41 
98.37 
98.15 
 
97.38 
98.15 
97.21 
 
101.84 
103.71 
101.65 
 
101.86 
99.20 
102.79 
 
99.41 
98.25 
101.84 
 
100.25 
101.85 
100.89 
 
98.34 
98.01 
99.27 
 
99.73 
100.36 
101.48 
Precision <2 <2 <2 <2 <2 <2 <2 <2 
*Mean of six determination 
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The statistical evaluation of the methods are summarized in table 45. 
Table 45:  Statistical comparison between the developed methods: 
 
Parameters  
Uv normal method  HPTLC HPLC Reported method(12)  
LEDI SOFO LEDI SOFO LEDI SOFO LEDI SOFO 
Mean  (assay) 99.39 99.53 101.56 99.52 99.40 99.44 99.37 99.46 
Number of points 6 6 6 6 6 6 6 6 
SD* 0.2779 0.2855 0.2556 0.3395 0.2526 0.2393 0.3883 0.2464 
SEM 0.1135 0.1166 0.1043 0.1386 0.1031 0.0977 0.1585 0.1006 
Medium 99.34 99.58 101.53 99.60 99.37 99.49 99.33 99.12 
P  0.0425 
F  1.056 
*Mean of six determination 
             This results shows that there is no significant difference among these methods. Hence, the developed methods can be used for routine 
analysis of ledipasvir and sofosbuvir from pharmaceutical dosage form. 
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